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Chapter 1 
 
Introduction 
 
Eph receptors and ephrins 
Eph receptors represent the largest family of receptor tyrosine kinases. 
The first member of this family was cloned in 1987 from an erythropoietin-
producing human epatocellular carcinoma cell line, from which the Eph 
receptors earned their name (Hirai et al., 1987). To date 16 vertebrate 
Eph receptors have been described, divided into two sub-groups based 
on sequences similarities and binding preferences for their ligands, the 
ephrins.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Binding interactions and sequence relationships of Eph receptors and 
ephrins. Green and purple indicate the high binding affinity to partners of the A or B 
class, respectively. Green with a purple center indicates high binding affinity to partners 
of the A class and low binding affinity to partners of the B class; purple with a green 
center indicates high binding affinity to partners of the B class and low binding affinity to 
partners of the A class. The question mark indicates that the binding preference of 
EphA10 receptor has not yet been determined. 
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There are 10 EphA (A1 through A10) and 6 EphB (B1 through B6) 
receptors, which preferentially bind to ephrins of the A or B class, 
respectively. Receptor-ligand interactions are promiscuous within each 
class, although binding affinities vary. Despite the initial classification, 
there are also some examples of inter-class binding: indeed, EphA4 can 
bind to all the ephrin B ligands, and EphB2 can bind to ephrin-A5 
(Himanen et al., 2004; Pasquale, 2004) (Fig. 1.1). 
Both the Eph receptors and the ephrins are membrane-bound 
molecules (Fig. 1.2). The Eph receptors are transmembrane proteins and 
they consist of an extracellular region responsible for ligand binding, a 
single transmembrane domain and a cytoplasmic region, where the 
catalytic activity resides (Fig. 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. (A) Domain structure of Eph receptors and ephrins. The ephrin-binding 
domains of Eph receptors are in different colors to indicate their different specificity for 
ephrin-A and ephrin–B ligands, respectively.  (B) Eph receptors-ephrin complex and 
associated signaling molecules. Eph receptor-ephrin binding results in the lateral 
aggregation of multiple Eph-ephrin complexes and the transphosphorylation of tyrosine 
residues (indicated in red) in the cytoplasmic region. This allows conformational 
changes in the receptor and ephrin structures and the association with intracellular 
signaling molecules, such as SH2 domain-containing proteins (SH2), PDZ domain-
containing proteins (PDZ) and guanine nucleotide exchange factors for Rho GTPases 
(GEF). 
 
 Chapter 1 
 9 
The extracellular region includes a conserved N-terminal ephrin-binding 
domain, a cysteine-rich linker, and two fibronectin type-III repeats, which 
seem to be involved in receptor dimerization (Lackmann et al., 1998). The 
ephrin-binding domains of EphB2 (Himanen et al., 1998) and EphB4 
(Chrencik et al., 2006) have been crystallized, showing a conserved 
jellyroll folding topology formed by 13 antiparallel beta-sheets. The 
cytoplasmic part of the Eph receptors consists of a juxtamembrane 
segment, a tyrosine kinase domain, a sterile-alpha-motif (SAM) domain, 
which is involved in receptor dimerization and signal transduction (Schultz 
et al., 1997; Stapleton et al., 1999), and a binding motif for post-synaptic 
density protein zona occludens (PDZ) domains. The juxtamembrane 
region contains 2 highly conserved tyrosine residues, which are the major 
autophosphorylation sites involved in receptor signaling (Bruckner and 
Klein, 1998; Holland et al., 1998). 
 The ephrin-B ligands are transmembrane proteins and contain 
conserved cytoplasmic regions, while the ephrin-A ligands are attached to 
the membrane through a glycosyl-phosphatidylinositol (GPI)-anchor at 
their C terminus. The receptor-binding domain of the ephrins of both the A 
and B class is conserved and has a Greek key beta-barrel folding 
topology (Nikolov et al., 2007; Nikolov et al., 2005). 
 
Eph-ephrin complex formation 
Binding of Eph receptors to their ephrin ligands leads to clustering, 
autophosphorylation and binding to intracellular signaling molecules, 
creating what is commonly called “forward signaling”.  In addition, ephrin 
clustering and downstream signaling also occurs, which is referred to as 
“reverse signaling”.   
 The crystal structures of the ligand binding domain of EphB2 in the 
apo form or in complex with ephrin-B2 or ephrin-A5 have elucidated how 
complex formation between Eph receptors and ephrins occurs (Himanen 
et al., 2001). The ephrin binding domain of EphB2 consists of two 
interfaces: a high affinity, hydrophobic cavity in the Eph receptor 
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extracellular domain, which accommodates the protruding G-H loop of the 
ephrin, and a low affinity interface on the opposite side. Two interfaces, 
one high affinity and the other low affinity, are also present on the surface 
of the Eph binding domain of the ephrin. The high affinity interfaces 
mediate the dimerization of the Eph receptors and ephrins, while the low 
affinity interfaces facilitate the formation of a heterotetramer, consisting of 
two Eph/ephrin heterodimers. Additional residues in both proteins also 
contribute to the binding surfaces, and both ligand and receptor undergo 
conformational changes, which in the case of EphB2 are different when 
the receptor is bound to different ligands.  
 A third molecular surface, located outside the crystallized domain, 
seems to help higher order oligomerization. Random mutagenesis of the 
EphA3 receptor revealed that a region located within the cysteine-rich 
linker also plays a role in EphA3 activation (Smith et al., 2004). A random 
mutagenesis approach was also used to identify the EphA3-interacting 
residues on ephrin-A5 surfaces, showing that a third interface is also 
present on the ephrin and it is located between the dimerization and the 
tetramerization sites (Day et al., 2005). Despite the presence of at least 
three binding interfaces, molecules that target the high affinity interface 
are sufficient to inhibit ligand-receptor binding (Chrencik et al., 2006; 
Koolpe et al., 2005; Koolpe et al., 2002; Murai et al., 2003b). 
 
Eph activation and signaling 
In the unphosphorylated form the Eph receptors are kept in an inactive 
state by the association of a helix from the juxtamembrane domain with 
the kinase domain (Wybenga-Groot et al., 2001). As a consequence of 
ephrin binding, the Eph receptors cluster and the kinase domains come in 
close proximity, favoring trans-phoshorylation of the cytoplasmic domains, 
which in turn releases the inhibitory interactions with the juxtamembrane 
domain and promotes kinase activity. 
 Tyrosine phosphorylation creates binding sites for Src-homology 2 
(SH2) domain-containing proteins, while the interaction with other 
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signaling proteins, such as PDZ-domain-containing proteins and guanine 
nucleotide exchange factors for Ras and Rho family proteins, are 
independent of the kinase activity of the receptor (Noren and Pasquale, 
2004). EphB6 and EphA10, which lack an active catalytic domain, can 
signal through kinase-independent pathways or can be phosphorylated by 
other receptors and bind cytoplasmic proteins.  
The reverse signaling, mediated by the activation of the ephrin, is 
better understood for the B-class ephrins, which can recruit intracellular 
signaling or adaptor proteins through their PDZ-binding domain or 
through phosphorylated tyrosines in their cytoplasmic region. The 
activation of the A-ephrins is poorly understood and may require the 
interaction with transmembrane proteins (Pasquale, 2005).  
 Eph signaling can mediate both cell attraction and cell repulsion. 
Given that both Eph receptors and ephrins are membrane bound 
molecules, their interaction occurs at sites of cell contact and mediates 
cell adhesion. However, Eph signaling causes contraction of the actin 
cytoskeleton and retraction of the cell periphery. Separation of the two 
adhering cell surfaces is enabled by endocytosis of Eph-ephrin 
complexes at sites of cell contact or by proteolitic cleavage of the ephrin 
or the receptor (Pasquale, 2005).  
 In many tissues, Eph receptors and ephrins are co-expressed in 
the same cells. Two different mechanisms have been reported to explain 
the role of Eph-ephrin coexistence. Eph receptors and ephrins can be 
segregated in different plasma membrane domains, where they can 
interact in trans with their partners on other cells, independently 
generating signals (Marquardt et al., 2005; Konstantinova et al., 2007). 
Alternatively, Eph receptors and ephrins could be intermixed in the same 
areas of the plasma membrane and interact with each other in cis, thus 
silencing forward and reverse signaling by preventing interaction with 
partners on other cells (Carvalho et al., 2006).  
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Eph functions 
Eph receptors and ephrins were originally identified as neuronal axon 
guidance molecules active during development. However, further studies 
showed how this family of receptors is involved in many other different 
activities, both during development and in the adult. 
 In the developing nervous system Eph-ephrin interaction is 
required to guide growing axons towards their targets through repulsive 
effects (Wilkinson, 2001). For example, axons with high Eph receptor 
expression avoid regions with high ephrin expression. Gradients of Eph 
receptors and ephrins help establish proper neuronal connections in 
many areas of the brain, including the olfactory and visual systems. Eph 
receptors and ephrins are also involved in patterning the vertebrate 
neuraxis (Lumsden and Krumlauf, 1996) and controlling the migration of 
neural crest cells (Wang and Anderson, 1997) and axon branching and 
fasciculation (Chen et al., 2004; Yates et al., 2001). Eph receptors and 
ephrins are also expressed in different cell types in the adult brain, 
although usually at lower levels compared to the developing stages. The 
functions of Eph receptors and ephrins in the adult brain remain partly 
unclear, but it appears that they may play an important role in the 
formation and plasticity of dendritic spines and synapses in the 
hippocampus (Murai et al., 2003a; Murai and Pasquale, 2002), which are 
processes involved in learning and memory.   
In addition to their roles in the neural system, the Eph receptors 
are involved in many other physiological processes. One of the most 
investigated is their activity in the development of the cardiovascular 
system (Kuijper et al., 2007; Zhang and Hughes, 2006). The cell shaping, 
migration and compartmentalization required during angiogenesis and 
remodeling of blood and lymphatic vasculature are regulated by repulsive 
Eph signals. Eph receptors and ephrins are also involved in the immune 
system, where they regulate T cell development and immune responses 
(Hjorthaug and Aasheim, 2007) and dendridic cell trafficking and function 
(de Saint-Vis et al., 2003; Munthe et al., 2004). 
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 Recent evidence suggests a role for Eph-ephrin signaling in the 
response of pancreatic β-cells to glucose. In the absence of glucose, Eph 
forward signaling, which inhibits insulin secretion, is predominant. In the 
presence of glucose, the cells shift to ephrin reverse signaling to enhance 
insulin secretion (Konstantinova et al., 2007). 
Eph-ephrin bidirectional signaling is also involved in the regulation 
of bone homeostasis (Zhao et al., 2006) and in platelet aggregation 
(Prevost et al., 2002; Prevost et al., 2005). 
 Finally, Eph receptors and ephrins are expressed in different types 
of stem cells, including skin, haematopoietic, neural, intestinal and 
embryonic stem cells, where they can influence self-renewal and 
differentiation (Pasquale, 2005). 
 
Targeting Eph receptors 
Given the wide distribution and multiple functions of the Eph receptors 
and their ligands, it is not surprising that they are involved in many 
diseases. The Eph receptors are upregulated after central nervous 
system injury, and they may inhibit axon regeneration by stimulating 
growth cone collapse, astrocytic glyosis and the formation of the glial scar 
(Goldshmit et al., 2006). Furthermore, many Eph receptors are 
overexpressed or dysregulated in different types of cancer, where they 
can affect tumor growth, tumor vascularization and metastatic 
dissemination. Therefore, targeting Eph receptors may be beneficial for 
central nervous system regeneration after injury and for the treatment of 
different types of cancer. Furthermore, given the role of Eph-ephrin 
interaction in promoting platelet aggregation and thrombus stability, 
blocking the Eph-ephrin signaling could be useful for the prevention of 
blood clotting under pathological conditions, such as stroke and coronary 
artery occlusion. Drugs targeting Eph signaling could also be used in 
diabetes and osteoporosis treatment, and to control stem cell migration 
and fate determination. 
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Aim of the work 
The goal of this work is the development and characterization of chemical 
compounds and peptides that inhibit Eph receptor-ephrin binding (Fig. 
1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The identification of such molecules will help in understanding the 
mechanism of recognition between the receptors and their ligands and 
will be useful for the treatment of diseases where Eph-ephrin interaction 
is involved. Some molecules that modulate Eph-ephrin signaling have 
already been identified, including agonistic and antagonistic peptides, 
antibodies and soluble portions of Eph receptors and ephrins (Carles-
Kinch et al., 2002; Conover et al., 2000; Koolpe et al., 2005; Koolpe et al., 
2002; Murai et al., 2003b; Noblitt et al., 2004). However none of the 
molecules identified so far have ideal pharmacological properties: they 
are difficult to make, not sufficiently stable or do not show adequate 
specificity. 
Although the interaction surface involved in Eph receptor-ephrin 
binding is relatively large, a survey analyzing the suitability of binding 
Figure 1.3. Molecules targeting the Eph-ephrin binding pocket can inhibit bidirectional 
signals, by disrupting the interaction between Eph receptors and ephrins. 
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pockets in terms of size, polarity and geometry of protein-protein 
interaction surfaces showed that the high affinity ephrin binding pocket of 
the Eph receptors is amenable to tight binding of a druglike compound 
(Fry and Vassilev, 2005). 
 In this study we focused on the identification of compound 
inhibitors targeting the Eph receptors EphA4 and EphA2 using high 
throughput screening or combinatorial approaches. We also modified 
TNYL-RAW, a potent peptide antagonist for EphB4, in order to improve 
its stability and delay its in vivo clearance from the blood circulation by 
coupling it with poly ethylene glycol (PEG) or the Fc portion of human 
IgG. 
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Chapter 2 
 
Small molecules that target the EphA4 receptor 
 
ABSTRACT 
The EphA4 receptor is a well-known regulator of axon guidance and tissue 
patterning during nervous system development. Recent evidence also links 
the expression and activity of this receptor to different pathological 
conditions, such as inhibition of spinal cord regeneration after injury, 
improper platelet aggregation and cancer. Thus, EphA4 is a promising 
novel target for drug development. Here we report the identification by high 
throughput screening of two 2,5-dimethylpyrrolyl benzoic acid derivatives 
that inhibit EphA4-ephrin binding and, among the large family of Eph 
receptors, are specific for EphA4 and EphA2 only. These compounds inhibit 
ephrin-dependent phosphorylation of EphA4 and EphA2 in cells, EphA4-
mediated growth cone collapse in retinal explants and EphA2-dependent 
retraction of the cell periphery in prostate cancer cells. The inhibitory 
activities of these compounds in cell biological assays suggest that they are 
promising lead compounds for the development of therapies to treat 
diseases in which EphA4 and EphA2 are involved. We also report some 
examples of artifacts that could be encountered when screening small 
molecule in a high throughput format. 
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INTRODUCTION 
The Eph family of tyrosine kinase receptors and their ligands, the ephrins, 
are critical regulators of nervous system development. Eph-ephrin signaling 
mediates axon pathfinding and helps organizing topographical maps during 
neural development by mediating repulsive cues (O'Leary and Wilkinson, 
1999; Wilkinson, 2001). EphA4 is a member of the A class of Eph receptors 
(see Introduction) and modulates diverse processes by interacting with both 
ephrin A and B ligands. Similar to other members of the Eph family, EphA4 
is involved in the development of the nervous system, where it helps 
organize and compartmentalize developing structures, usually by mediating 
repulsive signals in response to the binding to its ephrin ligands. For 
instance, during early development of the hindbrain and somites, EphA4 
signaling helps segregate anatomical compartment expressing the receptor 
from compartment expressing ephrin ligands (Mellitzer et al., 1999; Xu et 
al., 1995; Xu et al., 1999). Later in development, EphA4 is required in the 
corticospinal tract, where by interacting with ephrin-B3 expressed at the 
spinal cord midline it prevents contralateral corticospinal projections from 
recrossing the midline (Coonan et al., 2001; Dottori et al., 1998; Kullander 
et al., 2001; Yokoyama et al., 2001). EphA4 also regulates the trajectory of 
motor axons from the lateral motor column of the spinal cord to limb 
muscles (Eberhart et al., 2004; Eberhart et al., 2002). Finally, in the 
developing visual system EphA4 guides the topographical connections 
between retinal ganglion cells axons and the visual centers of the brain 
(Connor et al., 1998; Dutting et al., 1999; Hornberger et al., 1999; Reber et 
al., 2004). 
Despite being expressed at higher levels in the embryo, EphA4 is 
also present in the adult brain, particularly in synaptic-rich structures that 
show on-going remodeling, such as the hippocampus and the cortex (Murai 
et al., 2003a). In hippocampal pyramidal neurons, EphA4 is expressed in 
dendritic spines, which are the small dendritic protrusions where the 
excitatory synapses are located, and it regulates their morphological 
remodeling, which is believed to modulate synaptic plasticity and learning 
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and memory processes. Activation of EphA4 causes shortening and 
retraction of spines through mechanisms involving different signaling 
pathways, such as integrin signaling (Bourgin et al., 2007), phospholipaseγ1 
signaling (Zhou et al., 2007) and activation of a guanine nucleotide 
exchange factor for the RhoA GTPase (Fu et al., 2007). 
The EphA4 receptor has also been implicated in different 
pathological conditions. First, it has been shown to inhibit the ability of 
spinal cord neurons to re-grow after injury. Damage to the adult central 
nervous system usually results in very limited regeneration of lesioned 
axons. The limited capability of central nervous system neuron to 
regenerate is due to different factors, including the reduced intrinsic activity 
of mature axons to grow, the presence in the environment of myelin-
associated inhibitors and an excessive and ipertrophic response of glial 
cells, which form a barrier to the growth of axons called glial scar (Stichel 
and Muller, 1998). EphA4 is overexpressed and activated in glial cells at the 
site of spinal cord injury, consistent with the observation that inflammatory 
cytokines upregulate EphA4 expression in cultured astrocytes (Goldshmit et 
al., 2004). EphA4 knock-out mice show a significantly reduced glial scar 
and an improved ability to regenerate spinal cord connections after injury. 
Furthermore, EphA4 null astrocytes in culture lose their ability to respond to 
inflammatory cytokines (Goldshmit et al., 2004), suggesting that this 
receptor may play a role in the inhibition of axon regeneration in the spinal 
cord after injury. Here, EphA4 may act as a negative regulator of axon 
regeneration by mediating the formation of the glial scar and by stimulating 
ephrin reverse signaling in the axon. In addition, it has been shown that 
EphA4 accumulates in the damaged axons after injury and may interact 
with ephrin-B2 expressed in the surrounding astrocytes and ephrin-B3 
expressed in myelin, leading to an inhibitory response (Benson et al., 2005; 
Fabes et al., 2006). The relative importance of these different effects is not 
yet known, however it seems likely that inhibiting EphA4 function may be 
beneficial for the treatment of spinal cord injuries. Although one study 
showed that blockade of EphA4 expression at the site of spinal cord injury 
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with antisense oligonucletides does not induce axonal regeneration or 
return of nerve conduction (Cruz-Orengo et al., 2007), another study 
showed that infusion with a peptide specifically targeting EphA4, KYL 
(Murai et al., 2003b), into lesioned spinal cords results in improved axon 
sprouting, reduced cavity formation and improved behavioral recovery 
(Fabes et al., 2007).  
Besides their application in the treatment of spinal cord injury, EphA4 
inhibitors may be beneficial for the treatment of other diseases. Indeed, 
EphA4 is expressed on the surface of human platelets and its interaction 
with ephrin-B1 favors thrombus formation and stability by promoting integrin 
activation (Prevost et al., 2002; Prevost et al., 2005; Prevost et al., 2004). 
Inhibitors of EphA4-ephrin binding could help preventing blood clotting 
under pathological conditions, such as stroke and recurrent occlusion of the 
coronary artery, that are due to excessive or inappropriate platelet 
aggregation. Furthermore, EphA4 is overexpressed in prostate cancer 
(Ashida et al., 2004), particularly in the transition to more malignant stages. 
Prostate cancer cell growth is inhibited by small interfering RNA, showing 
how targeting EphA4 may be also beneficial in the treatment if this type of 
cancer.  Finally, EphA4 is also overexpressed in pancreatic ductal 
adenocarcinoma, where its interaction with ephrin-A3 promotes cancer cell 
growth (Iiizumi et al., 2006). 
Compounds identified by targeting EphA4 could serve both as tools to study 
the physiological roles of this receptor and as leads for drug development. 
However, no small molecule inhibitors of EphA4 have been identified so far. 
Small molecules are chemical compounds with a molecular weight lower 
than 500 Da, and they usually show better pharmacological properties 
compared to peptide and antibodies. Several small molecule inhibitors that 
target the kinase domain of tyrosine kinases have been identified. However, 
given the conservation of the kinase domains, these inhibitors typically 
target multiple kinase families. In this study we report the identification by 
high through-put screening of two 2,5-dimethylpyrrolyl benzoic acid 
derivatives that inhibit EphA4 binding to ephrin and EphA4 function. 
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MATERIALS AND METHODS 
Chemical library screening for EphA4 inhibitors 
A 96-well or 384-well format in vitro assay was used for compound 
screening. Polystyrene high binding capacity plates (Corning, Corning, NY) 
were incubated overnight at 4°C with 2 µg/ml streptavidin (Pierce 
Biotecnology, Rockford, IL) diluted in borate buffer 0.1 M pH 8.7 and then 
coated by overnight incubation with 0.1 µM of biotinylated KYL peptide in 
binding buffer (Tris-buffered saline (TBS) (150 mM NaCl; 50 mM Tris-HCl, 
pH 7.5 plus 1mM CaCl2 and 0.01% Tween 20). Compounds were added to 
the wells at 10 µg/ml in 100% dimethylsulfoxide (DMSO) together with 
EphA4 alkaline phosphatase fusion protein (EphA4 AP) produced from 
transfected cells. Cell culture medium containing the secreted EphA4 AP 
was diluted 1: 16 in binding buffer. The mixture was incubated for 3 hours at 
room temperature before adding p-nitrophenylphosphate (pNPP) (Pierce 
Biotecnology, Rockford, IL) as substrate. After 1 hour the reaction was 
stopped by adding 2N NaOH and the absorbance at 405 nm was measured 
using an ELISA plate reader. Alkaline phosphatase activity from wells 
where alkaline phosphatase (AP) was added instead of EphA4 AP was 
subtracted as background. The inhibitory activity of the compounds was 
calculated by dividing the absorbance observed in the presence of each 
compound and the absorbance from wells where no compound was added. 
Compounds with inhibitory activity higher than 50% were considered hits. 
The inhibitory activity of the hits was confirmed by repeating the assay. 
  
ELISA assays and Ki determination 
Protein A-coated wells (Pierce Biotecnology, Rockford, IL) were used to 
immobilize ephrin Fc fusion proteins (R&D Systems, Minneapolis, MN). 
Compounds at different concentrations were incubated with EphA4, EphA2 
or EphB4 AP for 3 hours. Alternatively, Eph receptor Fc fusion proteins 
were immobilized on protein A-coated wells and ephrin-A5 AP or ephrin-B2 
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AP was added with the compounds. In order to test if the inhibition 
observed was reversible, an assay where the compounds were removed 
and the wells washed for 3 hours before the addition of the AP fusion 
protein was also performed. The amount of bound AP-fusion protein was 
quantified using pNPP. Alkaline phosphatase activity from wells with Fc only 
was subtracted as background. 
 
For estimations of the inhibition constant (Ki) values, the binding of 
ephrin-A5 AP to EphA4 Fc immobilized on protein A-coated wells was 
measured in the absence or in the presence of the compounds at different 
concentrations. Each data set was fitted to the Michaelis-Menten equation 
(Equation 1) using non linear regression and the program GraphPad 
(Prism).  
 
B = Bmax [S]/(KD + [S])                                                                  (Equation 1) 
 
where [S] is the concentration of ephrin AP fusion protein  and KD is the 
dissociation constant observed in the absence or in the presence of the 
compound. 
To evaluate whether the inhibition is competitive, non competitive or 
uncompetitive the KD and the Bmax values were determined at different 
compound concentrations. The Ki was obtained from the linear regression 
plot of KD/Bmax as a function of the concentration of the inhibitor according 
to: 
 
KD/Bmax = (KD [S])/(Ki ·Bmax) + KD/Bmax                                                               (Equation 2) 
 
Alternatively, Ki values were obtained from the dose response curves, using 
the Cheng-Prusoff equation (Cheng and Prusoff, 1973): 
 
Ki = IC50/(1 + [S]/KD)                                                                    (Equation 3) 
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Assays to identify nonspecific inhibitors 
Goat anti-EphA4 antibody (R&D Systems, Minneapolis, MN) was 
immobilized on protein G-coated wells (Pierce Biotecnology, Rockford, IL), 
followed by the addition of EphA4 AP containing medium diluted 1:16 in 
binding buffer. The receptor immobilized in the wells was incubated with the 
compounds in 100% DMSO for 3 hours before washing the compounds off 
the plate and adding pNPP substrate. Absorbance was measured at 405 
nm. In some experiments, after removing the solution containing unbound 
EphA4 AP and compounds, the wells were incubated for an additional 3 
hours in binding buffer, to examine whether the inhibitory effects of the 
compounds were reversible. In other experiments, the wells were not 
washed before measuring AP activity to discriminate between inhibition of 
alkaline phosphatase activity and inhibition of binding interactions. 
Experiments where compounds were: (1) added to protein G-coated wells 
and washed off before the addition of the anti-EphA4 antibody or (2) added 
to the immobilized anti EphA4 antibody and washed off before adding 
EphA4 AP were also performed. The results were normalized to alkaline 
phosphatase activity from wells containing the same amount of DMSO but 
without the compounds.  
 
Measurement of receptor tyrosine phosphorylation in cells 
HT22 neuronal cells, which endogenously express EphA4, and COS7 cells, 
which endogenously express EphA2, EphB2 and the EGF receptor (EGFR) 
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Mediatech, 
Inc, Herndon, VA) with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) 
and Pen/Strep. For EphA4 immunoprecipitations, HT22 cells were serum-
starved overnight in 0.5% FBS in DMEM and incubated for 15 min with the 
compounds or DMSO as a control. The cells were then stimulated with 0.5 
µg/ml ephrin-A5 Fc or Fc protein for 20 min in the presence of the 
compounds. After stimulation the cells were lysed in modified RIPA buffer 
(1% Triton X-100, 1% Na deoxycholate; 0.1 SDS; 20 mM Tris; 150 mM 
NaCl; 1 mM EDTA) containing 10 µM NaF, 1 µM sodium pervanadate and 
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protease inhibitors. The protein concentration was calculated using the BCA 
protein assay kit (Pierce Biotecnology, Rockford, IL). Cell lysates were 
immunoprecipitated with 4 µg anti-EphA4 antibody. For EphA2 and EphB2 
immunoprecipitations, serum-starved COS7 cells were stimulated with 0.1 
µg/ml ephrin-A1 Fc or 0.5 µg/ml ephrin-B2 Fc, respectively. The cells were 
then lysed and incubated with 2 µg of anti-EphA2 antibody (Millipore, Inc, 
Temecula, CA) or 7 µg anti-EphB2 antibody.  
To assess EGFR phosphorylation, COS7 cells were serum-starved 
overnight in 0.2% FBS in DMEM. The cells were preincubated with the 
compounds as described above and then stimulated for 15 min with 0.1 µM 
EGF. Immunoprecipitates and lysates were probed by immunoblotting with 
anti-phosphotyrosine antibody (Millipore, Inc, Temecula, CA) and reprobed 
with anti-Eph receptor antibodies followed by a secondary anti-IgG 
peroxidase-conjugated antibody (GE Healthcare, UK). 
 
MTT assay 
The cytotoxicity of the compounds was measured using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric 
assay. Cells were seeded in a 96 well plate and treated with compounds or 
DMSO starting 3, 2 or 1 day before they reached 100% confluency. For the 
assay, MTT (Sigma-Aldrich, Steinheim, Germany) was added at a final 
concentration of 0.5 µg/ml and incubated with the cells for 3 hours. The 
resulting formazan crystals were then solubilized by addition of 100% 
DMSO. The absorbance in each well was measured at 570 nm using an 
ELISA plate reader. The results were expressed as the ratio of the 
absorbance of the treated and untreated cells. 
 
PC3 cell retraction 
 PC3 cells were plated onto glass coverslips and grown in RPMI 1640 
medium (Mediatech, Inc, Herndon, VA) with 10% FBS and Pen/Strep. After 
17 hours the cells were starved for 3 hours in 0.5% FBS in DMEM and then 
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incubated for 40 min with the compounds or DMSO, before stimulation for 
10 min with 0.5 µg/ml of ephrin-A1 Fc or Fc as a control. The cells were 
fixed in 4% formaldehyde in PBS, permeabilized in 0.5% Triton X-100 in 
TBS and stained with rhodamine-conjugated phalloidin (Molecular Probes) 
and DAPI. Cell area was measured in a blinded manner using ImageJ 
software and normalized to the average area obtained in the Fc stimulated 
condition. Cells having rounded shape and area equal or below 20% of the 
control area were considered as retracting.  
 
Growth cone collapse assay 
Nasal retina explants from E6 chicken embryos were cultured on polylysine- 
(200 µg/ml) and laminin- (20 µg/ml) coated coverslips for 12 to 24 hours in 
DMEM/F-12 containing 10% FBS and 0.4% methylcellulose. Three hours 
before adding the Fc fusion proteins, the medium was changed to DMEM/F-
12 without methylcellulose. The explants were incubated for 15 min with the 
KYL peptide or the compounds and then stimulated for 30 min with 1 µg/ml 
of preclustered ephrin-A5 Fc or Fc as a control. The cultures were fixed for 
30 min in 4% paraformaldehyde/4% sucrose, permeabilized in 0.1% Triton 
X-100 and stained with rhodamine-conjugated phalloidin (Invitrogen, 
Carlsbad, CA). Growth cones where scored in a blinded manner as 
collapsed when no lamellipodia or filopodia were present at the tip of the 
neurite, as not collapsed when lamellipodia or more than 3 filopodia were 
present and as partially collapsed in the other cases. 
 
 
RESULTS AND DISCUSSION 
High throughput chemical library screening to identify lead 
compounds that inhibit ligand binding to the EphA4 receptor 
To identify small molecule inhibitors of ligand binding to the EphA4 receptor, 
an assay was designed that takes advantage of a 12 amino acid peptide 
ligand previously identified by phage display (Murai et al., 2003b). The 
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peptide – known as KYL – has some sequence similarity with the ephrin-A 
G-H loop, which mediates high affinity binding to Eph receptors (Himanen et 
al., 1998). Furthermore, the KYL peptide was shown to competitively inhibit 
ephrin binding to EphA4, suggesting that it targets the high affinity ligand-
binding site of the receptor (Murai et al., 2003b).  
The biotinylated KYL peptide was immobilized on streptavidin-coated 
ELISA wells and binding of the extracellular domain of EphA4 fused to 
alkaline phosphatase (EphA4 AP) was measured in the presence of 
chemical compounds. Two screens were performed, where 10,000 
compounds from the DIVERSetTM library (ChemBridge, Inc.) and 61,500 
compounds from NIH were tested at 10 µg/ml in a 96- and 384- well format, 
identifying 43 and 80 compounds, respectively, that inhibited EphA4 AP 
binding by more than 50% in both the original screen and in a rescreen of 
the hits.  
Compound showing a reproducible high inhibition of EphA4-KYL 
binding were then tested for inhibition of EphA4 interaction with one of its 
ligands, ephrin-A5. 
 
Some of the hits in the high throughput screen for EphA4 antagonists 
act by a nonspecific mechanism  
Compound 1*, 1-(2-fluorophenyl)-5-(2-furanylmethylene) dihydro-2-thioxo-
4,6(1H,5H)-pyrimidinedione, a derivative of barbituric acid, showed a 
reproducible 97% inhibition of EphA4-KYL binding in the high throughput 
screen. The IC50 for inhibition of EphA4-KYL and EphA4-ephrin-A5 binding 
were 3 and 40 µM, respectively (Fig. 2.1A). Compound 1* inhibited ephrin-
binding to all EphA and EphB receptors except EphA7 and EphB5 (Fig. 
2.1B). When tested for inhibition of EphA4 binding to different ephrin-A 
ligands, it showed inhibitory activity towards all ephrins, with the exception 
of ephrin-A4 (Fig. 2.1C).  Compound 1* at 100 µM also inhibited EphA4, 
EphB4 and EphA2 phosphorylation in cells stimulated with ephrin-A5 Fc, 
ephrin-B2 Fc and ephrin-A1 Fc, respectively (Fig. 2.2A-C).  
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Cell viability after 17 hours and EGFR phoshorylation in response to EGF 
stimulation were not affected by treatment with up to 200 µM of compound 
1* (Fig. 2.2D and data not shown), suggesting that the compound is not 
toxic and that it is not a general inhibitor of receptor tyrosine kinases. 
However, when the compound was tested in ELISA assays aimed at 
determining whether the observed inhibition was reversible or irreversible, 
compound 1* showed some peculiar properties. EphA4 was immobilized on 
ELISA wells and incubated with compound 1*, followed by washes and 
incubation in binding buffer for several hours before adding ephrin-A5 AP. 
Under these conditions, ephrin-A5 binding was restored even in the 
presence of the compound (Fig. 2.3A). However, when the same 
experiment was performed by measuring EphA4 AP binding to immobilized 
ephrin-A5, no reduction in activity was observed several hours after 
removing the compound, suggesting that the compound binds to ephrin-A5 
in an irreversible way (Fig. 2.3B).  
Fig. 2.1. Compound 1* inhibits ephrin-binding to EphA and EphB receptors. (A) 
Compound 1* inhibits EphA4 binding to immobilized KYL peptide (blue) and ephrin-A5 
binding to immobilized EphA4 (black) in a concentration-dependent manner. (B) Ephrin-
A5 AP or ephrin-B2 AP binding to immobilized EphA or EphB receptors, respectively, was 
measured in the presence of the indicated concentrations of compound 1* . The ratio of 
ephrin AP bound in the presence and in the absence of compound is shown. (C) EphA4 
AP binding to ephrin-A ligands immobilized on protein A-coated plates was detected. The 
ratios of EphA4 AP bound in the presence and in the absence of the indicated 
concentrations of compound 1* are shown. Bars indicate the standard error from triplicate 
measurements in all the panels. 
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Interestingly, despite binding to ephrin-A5 but not to EphA4, 
compound 1* was identified in an assay based on EphA4-KYL binding 
inhibition, which did not involve the ephrin. An additional ELISA assay with 
the immobilized KYL peptide was then performed, which demonstrated that 
compound 1* also exhibits irreversible activity with the peptide (Fig. 2.3C). 
The hypothesis that compound 1* covalently binds to the KYL peptide was 
confirmed by electrospray ionization mass spectrometry, which was 
performed by the Medicinal Chemistry facility of the Burnham Institute for 
Medical Research. Indeed, the mass spectrum of the peptide incubated with 
and without compound 1* showed a 317 Da shift in the peak corresponding 
Fig. 2.2. Compound 1* inhibits EphA4, EphA2 and EphB4 phosphorylation in cells 
without affecting their viability. (A-C) Cells pretreated with the indicated concentrations 
of compound 1* for 15 min were stimulated for 20 min with ephrin Fc (+) or Fc as a control 
(–) in the continued presence of the compound. Eph receptors immunoprecipitates were 
probed with anti-phosphotyrosine antibody (PTyr) and reprobed with the indicated anti-
Eph antibody. C indicates the immunoprecipitations performed with control IgG. HT22 
cells (A), MDA-MB-435 cells (B) and COS7 cells (C) were stimulated with ephrin-A5 Fc, 
ephrin-B2 Fc or ephrin-A1 Fc, respectively, and EphA4, EphB4 or EphA2 were 
subsequently immunoprecipitated as indicated. (D) HT22 cells were grown in the 
presence of compound 1* at the indicated concentration for 40 min, 3 hours or 17 hours. 
DMSO only was used in the “0 µM” sample. After addition of MTT the absorbance was 
measured at 570 nm. The histogram shows the absorbance obtained under each 
condition normalized to the value obtained in the control. Bars represent the standard 
error from triplicate measurements.  
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to the peptide mass, which is the exact molecular weight of compound 1* 
(Fig. 2.3D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fact that compound 1* is a reactive molecule which could undergo 
chemical reactions such as electrophilic addition at the sulfur atom supports 
the idea that it acts through covalent binding. It would be interesting to 
identify which amino acid is covalently modified by the compound. Although 
some covalent-acting drugs identified through biological assays are 
effective antibiotics or antineoplastic agent, when these types of 
Fig. 2.3. Compound 1* irreversibly binds to the KYL peptide. (A-C) Ephrin-A5 AP (A) 
or EphA4 AP (B, C) binding to immobilized EphA4 Fc (A), ephrin-A5 Fc (B) or KYL peptide 
(C) was measured after  incubating compound 1* at the indicated concentrations together 
with the AP fusion proteins (black). Alternatively, compound 1* was removed before 
addition of the AP fusion proteins, in order to assess whether the compound was 
irreversibly bound (green). (D) The KYL peptide was preincubated for 2 hours with an 
excess of compound 1* before performing electrospray ionization mass spectrometry. 
Peptide MW = 1465, peptide + compound MW = 1782.  
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compounds are developed using biochemical screens they often have 
nonspecific activities and are therefore not suited for further development 
(Rishton, 2003). 
 Another set of molecules that were identified in the second EphA4 
high throughput screen initially showed promising features, having IC50 
values for inhibition of EphA4-ephrin-A5 binding in the low micromolar 
range. Three of these molecules, compounds 2*, 3* and 4*, are shown in 
Fig. 2.4A. When these compounds were tested in a control experiment 
involving EphA4 AP immobilized through an anti-EphA4 antibody to protein 
G-coated ELISA plates, however, they showed an inhibition level 
comparable to the one obtained in the EphA4-ephrin-A5 assay, suggesting 
that the observed effect was not specific. The inhibition could be due to 
inhibition of AP activity or to a nonspecific inhibition of one of the protein-
protein interactions involved in the assay. None of the compounds inhibited 
AP activity of EphA4 AP or placental alkaline phosphatase (PLAP) in 
solution, indicating that they are not AP inhibitors (Fig. 2.4B).   
In order to better understand the behavior of these compounds, 
additional ELISA assays were performed (Experiments. I-V; Fig. 2.4C). The 
effects of compounds 2*-4* were observed even when the ELISA wells 
were washed for several hours before measuring AP activity (Exp. II).  
Compounds 2* and 4* showed inhibition when added before EphA4 AP to 
anti-EphA4 antibody immobilized on the wells (Exp. III), but not when added 
to the wells before the anti-EphA4 antibody (Exp. IV), suggesting that they 
inhibit the interaction between the anti-EphA4 antibody and EphA4 AP. In 
contrast, compound 3* showed inhibitory activity both when added to 
protein G-coated plates before the anti-EphA4 antibody and when added 
after the anti-EphA4 antibody and before EphA4 AP, suggesting that this 
compound inhibits at least partially the interaction between protein G and 
the anti-EphA4 antibody. Compound 3* is a charged reactive molecule, a 
feature that could explain its promiscuous activity, which is likely due to 
covalently nonspecific binding through conjugate addition.  
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In order to test the hypothesis that compounds 2*-4* act by 
nonspecifically disrupting protein-protein interactions, the experiment where 
the compounds were added to EphA4 AP immobilized through anti-EphA4 
antibody to ELISA plates was repeated without washing the compounds off 
before measuring AP activity (Exp. V). If the hypothesis is correct, no 
decrease of alkaline phosphatase activity should be observed in this assay. 
This is what we observed for compound 2*, but not for compounds 3* and 
4*. The behavior of compounds 3* and 4* was unexpected, and so far not 
explained. 
Small molecule high throughput screens have become one of the 
most exploited tools in drug discovery. Although being a powerful tool for 
the identification of new drugs, high throughput screening results can 
sometimes be ambiguous and lead to artifacts. Such artifacts can be due to 
a variety of factors, including chemical reactivity, oxidation, optical opacity, 
perturbation of the assay or the detection method and nonspecific inhibition 
due to formation of aggregates (Rishton, 2003; Shoichet, 2006). In the high 
throughput screens for small molecule inhibitors of EphA4 receptor we 
encountered some of these artifacts, including chemical reactivity and 
nonspecific inhibition of protein-protein interactions, in addition to 
nonspecific inhibition of unknown nature. The prompt identification of such 
nonspecific inhibitors through the use of appropriate control experiments is 
indispensable in order to eliminate them as leads for drug development and 
focus on compounds with better pharmacological properties. 
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Two 2,5-dimethylpyrrolyl benzoic acid derivatives selectively target 
the EphA4 and EphA2 receptors 
Among the hits identified in the high throughput screens for EphA4 
inhibitors, 4 had a 2,5-dimethylpyrrolyl benzene scaffold (Table 2.1) and 
inhibited EphA4 AP binding to the KYL peptide with IC50 values ranging 
from 2 to 56 µM.  
Importantly, compound 1, 2-hydroxy-4-(2,5-dimethyl-1-pyrrolyl)benzoic acid 
also inhibited binding of ephrin-A5 AP to the EphA4 extracellular domain 
with an IC50 value of 13 µM (Fig. 2.5). The concentrations needed to inhibit 
ephrin binding were higher than those required to inhibit KYL binding, which 
was expected given that the ephrin binds EphA4 with higher affinity 
compared to the peptide.  
Unlike compound 1*, compound 1 appeared to be a reversible inhibitor, 
because its activity was reverted by several hours of incubation in binding 
buffer before the addition of ephrin-A5 AP or EphA4 AP to EphA4 Fc or 
ephrin-A5 coated plates, respectively (data not shown). Furthermore, unlike 
compounds 2*-4*, compound 1 did not show any activity in the control 
Fig. 2.4. Many compounds identified by HTS for EphA4 antagonists are non-
specific inhibitors. (A) Structures of compounds 2*, 3* and 4*. EphA4 AP binding to 
ephrin-A5 Fc immobilized to protein A-coated plates was measured in the presence or 
in the absence of compounds and was detected by alkaline phosphatase activity 
(black). EphA4 AP was also immobilized to protein G coated plates through an anti-
EphA4 antibody and alkaline phosphatase activity was measured in the presence or in 
the absence of compounds (purple), in order to measure inhibition of alkaline 
phosphatase activity or other non-specific inhibition. (B) Placental alkaline phosphatase 
or EphA4 AP in solution were incubated with 5 µM of compound 2* and 4* or 100 µM of 
compound 3*, followed by measurement of alkaline phosphatase activity. Levamisole a 
known inhibitor of alkaline phosphatase, was used as a control at 5 mM (C) Compounds 
2*, 3* and 4* were tested in ELISA assays using EphA4 AP immobilized to protein G- 
coated plates through an anti-EphA4 antibody as described in (A). Experiment I – 
Compounds were added after EphA4 AP had been immobilized on the plate and the 
wells were washed before measuring alkaline phosphatase activity. Experiment II – The 
same experiment as in I was performed, but the wells were washed for 3 hours before 
measuring alkaline phosphatase activity. Experiment III – Compounds were added to 
the plate after immobilizing the anti-EphA4 antibody and the wells were washed before 
adding EphA4 AP. Experiment IV – Compounds were added to protein-G plates and the 
wells were washed before adding the anti-EphA4 antibody. Experiment V – The same 
experiment as in I was performed, but without washing the wells before measuring 
alkaline phosphatase activity. In all the experiments measurements were normalized to 
alkaline phosphatase activity in the absence of compounds. Bars indicate standard 
errors from triplicate measurements in all the panels.  
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assay involving EphA4 AP immobilized through an anti EphA4 antibody to 
protein G-coated plates (data not shown). These results suggest that 
compound 1 inhibits the binding of the EphA4 receptor to both a synthetic 
peptide ligand and a natural ephrin ligand by a specific and non-covalent 
reversible mechanism.  
 
TABLE 2.I. Hits identified in the high throughput screen for EphA4 inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fifty-six additional compounds belonging to the same class as 
compound 1 were obtained from ChemBridge and other sources and were 
tested for inhibition of EphA4-KYL and EphA4-ephrin binding. Compound 5 
– a 1,2-isomer of compound 1 – also inhibited binding of ephrin-A5 AP to 
immobilized EphA4. The IC50 value for inhibition of EphA4-KYL peptide 
binding by compound 5 was 3 µM and for inhibition of EphA4-ephrin-A5 
binding was 9 µM (Fig. 2.5). 
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Fig. 2.5.Small molecules identified by high throughput screening inhibit ephrin-A5 
binding to EphA4 in a competitive manner. Compound 1 and compound 5 inhibit 
EphA4 AP binding to immobilized biotinylated KYL peptide and ephrin-A5 AP binding to 
immobilized EphA4 ectodomain Fc in a concentration-dependent manner, as shown in the 
two top panels for each compound. The bottom-left panels show the binding of ephrin-A5 
AP to immobilized EphA4 Fc in the presence of different concentration of each 
compound.(●) 0 µM (○) 10 µM (■) 20 µM (□) 30 µM (▲) 40 µM (∆) 50 µM. In the bottom-
right panels the dissociation constants, obtained using non-linear regression, were plotted 
against the compound concentrations in order to determine Ki values. Error bars indicate 
standard error from triplicate measurements.  
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Ephrin-A5 AP binding curves were measured at different compound 
concentrations, showing that compounds 1 and 5 competitively inhibit 
EphA4-ephrin-A5 binding with Ki values of 9 µM and 7 µM, respectively 
(Fig. 2.5). These data suggest that compounds 1 and 5 target the high 
affinity ephrin-binding site of the Eph receptors. The Ki value can also be 
obtained from the IC50 value and the dissociation constant (KD) for receptor-
ligand binding, using the Cheng-Prusoff equation (see Material and 
Methods). The Ki values for compound 1 and compound 5 calculated from 
the inhibition curves shown in Fig. 2.5 were 8 and 6 µM, respectively. 
Inhibition constants were also calculated from other IC50 values obtained 
using different ephrin concentrations, finding values ranging from 8 to 10 
µM for compound 1 and from 6 to 8 µM for compound 5 (data not shown). 
These values are consistent with each other and with the Ki values 
calculated from the binding curves. The Cheng-Prusoff equation was also 
applied to EphA2-ephrin-A5 binding, obtaining Ki values ranging from 11 to 
14 µM for compound 1 and from 10 to 13 µM for compound 5 (data non 
shown). 
Interestingly, despite the small size of the compounds, which is 298 
Da, and the ability of ephrin ligands to bind promiscuously to different Eph 
receptors, compounds 1 and 5 efficiently inhibited ephrin binding only to 
EphA4 and EphA2 but not any of the other EphA or EphB receptors 
examined (Fig. 2.6A). Both compounds inhibited binding to EphA4 of all 
ephrin ligands except ephrin-A4, ephrin-B1 and ephrin-B2, suggesting that 
the binding interactions of EphA4 with these ephrins are distinct from those 
with other ephrins. Similar inhibitory effects were obtained for EphA2-
ephrin-A binding, suggesting that ephrin-A4 also interacts with EphA2 
differently than other ephrins (Fig. 2.6B). The binding of ephrin-A2, ephrin-
A3 and ephrin-A5 to EphA2 and EphA4 is similarly inhibited by the 
compounds, while ephrin-A1 binding to EphA2 is less easily inhibited 
compared the binding of this ligand to EphA4. 
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Compound 1 and compound 5 inhibit EphA4 and EphA2 activation by 
ephrin in cells without showing toxicity 
Given the promising results obtained in the ELISA assays, the two 2,5-
dimethylpyrrolyl benzoic acid derivatives were tested for their ability to 
inhibit EphA4 and EphA2 activation in cells. HT22 neuronal cells stimulated 
with ephrin-A5 Fc and incubated with compound 1 or 5 showed a 
significantly lower level of EphA4 phosphorylation on tyrosine residues 
compared to cells treated with DMSO as a control (Fig. 2.7A-B).  
 
 
Fig. 2.6. Compounds 1 and 5 show selectivity in their inhibition of different Eph 
receptors or ephrins. (A) Ephrin-A5 AP or ephrin-B2 AP binding to immobilized EphA or 
EphB receptor Fc fusion proteins was measured in the presence of the indicated 
concentrations of compounds 1 and 5. The ratio of ephrin AP bound in the presence and 
in the absence of compounds is shown. Bars indicate standard error from triplicate 
measurements. (B) IC50 values for compounds 1 and 5 inhibition of EphA4 AP or EphA2 
AP binding to the indicated ephrins immobilized on protein A-coated plates. 
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Fig. 2.7. Compounds 1 and 5 inhibit the ligand-induced phosphorylation of EphA4 
and EphA2 but not that of EphB2 or the EGF receptor in cells. (A) HT22 neuronal 
cells pretreated with the indicated concentrations of compounds 1 or 5 for 15 min were 
stimulated with 0.5 µg/ml ephrin-A5 Fc (+) or Fc as a control (-) for 20 min in the continued 
presence of the compounds. EphA4 immunoprecipitates were probed with anti-
phosphotyrosine antibody (PTyr) and reprobed with anti-EphA4 antibody. C indicates 
immunoprecipitations performed with control IgG. (B) The histogram shows the relative 
levels of EphA4 phosphorylation quantified from the experiment in (A) and normalized to 
the EphA4 levels in the immunoprecipitates. Error bars indicate the standard error from at 
least 3 experiments. (C) COS7 cells were stimulated with 0.1 µg/ml of ephrin-A1 Fc or Fc 
as a control in the absence or presence of the indicated concentrations of compounds 1 
and 5. EphA2 immunoprecipitates were probed with anti-phosphotyrosine antibody and 
reprobed for EphA2. C indicates the immunoprecipitations performed with control IgG. (D) 
The histogram shows the relative levels of EphA2 phosphorylation quantified from the 
experiment in (B) and normalized to the EphA2 levels in the immunoprecipitates. Bars 
represent the standard error from 2 experiments (E) The same protocol described in (C) 
was used, except that COS7 cells were stimulated with 0.5 µg/ml of ephrin-B2 Fc and the 
EphB2 receptor was immunoprecipitated. (F) COS7 cells pretreated with the indicated 
concentrations of compounds 1 or 5 were stimulated with EGF (+) or left unstimulated (–). 
Lysates were probed with anti-phosphotyrosine antibody. Receptor phoshorylation levels 
were compared with those in ephrin-stimulated samples in the absence of compounds by 
one-way ANOVA and Dunnett’s post test. * P<0.05 and ** P<0.01. 
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Similar results were obtained for EphA2 in COS7 cells stimulated with 
ephrin-A1 Fc, where treatment with 200 µM of either compound almost 
completely abolished EphA2 phosphorylation (Fig. 2.7C-D). The presence 
of the compounds also counteracted ephrin-mediated internalization and 
degradation of EphA2. It is interesting to note that previously identified 
EphA2-targeting peptides were able to inhibit EphA2-ephrin binding in 
ELISA assays but, unlike the newly identified small molecules, stimulated 
EphA2 phosphorylation in cells and acted as agonists rather than 
antagonists (Koolpe et al., 2002). In a control experiment, COS7 cells were 
also stimulated with ephrin-B2 Fc in order to activate EphB2. Consistent 
with the results obtained in the ELISA assays, compounds 1 and 5 did not 
inhibit EphB2 phosphorylation (Fig. 2.7E). As an additional control, the 
effects of the compounds on EGF receptor phosphorylation were measured. 
Concentrations of up to 400 µM of compounds 1 and 5 did not alter EGF 
receptor activation in COS7 cells stimulated with EGF (Fig. 2.7F). The 
toxicity of the compounds was also assessed by using the MTT assay. 
These experiments showed that compounds 1 and 5 at concentrations up to 
400 µM do not affect HT22 cell viability when incubated with the cells for up 
to 3 days (Fig. 2.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.8. Compound 1 and compound 5 do not have toxic effects in cell culture. 
HT22 neuronal cells were grown in the presence of compound 1 (A) or compound 5 (B) at 
the indicated concentration for 1, 2 or 3 days.  DMSO in place of the compounds was 
used in the “0 µM” sample, as a control. After addition of MTT the absorbance was 
measured at 570 nm. The histograms show the absorbance obtained for each condition 
normalized to the absorbance in the absence of the compounds. Bars represent standard 
error from triplicate measurements.  
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Compound 1 and compound 5 inhibit EphA2-mediated retraction of 
the cell periphery  
EphA2 is known to induce changes in cell morphology when activated by 
ephrin-A1 (Dail et al., 2006; Miao et al., 2000). PC3 prostate cancer cells  
express EphA2 (Miao et al., 2001) and have been shown to undergo 
retraction of the cell periphery and rounding after stimulation with ephrin A1 
Fc (Parri et al., 2005). These cells were therefore used to examine whether 
compound 1 and compound 5 are able to interfere with EphA2-mediated 
cell retraction. Treatment with the compounds inhibited EphA2 activation 
(Fig. 2.9A-B) and ephrin-A1 induced PC3 cell retraction (Fig. 2.9C-H) 
without affecting cell morphology in the absence of ephrin treatment. 
Ephrin-A1 Fc treatment caused an increase in the percentage of retracting 
cells (Fig. 2.9D, G) and a decrease in the average cell area (Fig. 2.9E, H). 
Treatment with 100 µM of the dimethylpyrrolyl benzoic acid derivatives 
inhibited these effects. Interestingly, the compounds at 100 µM only partially 
inhibited EphA2 phosphorylation, suggesting that substantial levels of 
EphA2 activation may be required to promote the changes in cell 
morphology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.9. Compounds 1 and 5 inhibit ephrin-induced retraction of PC3 prostate 
cancer cells. (A-B) PC3 cells pretreated for 15 min with the indicated concentrations of 
compound 1 or compound 5 were stimulated with 0.5 µg/ml ephrin-A1 Fc (+) or Fc as a 
control (–) for 20 min in the continued presence of the compounds. EphA2 
immunoprecipitates were probed with anti-phosphotyrosine antibody and reprobed with 
anti-EphA2 antibody. C indicates the immunoprecipitations performed with control IgG. 
The histogram in (B) shows the relative levels of EphA2 phosphorylation, which were 
normalized to the amount of EphA2 in the immunoprecipitates. Error bars indicate 
standard error from 3 experiments. Receptor phoshorylation levels were compared with 
the ephrin-stimulated sample by one-way ANOVA and Dunnett’s post test. * P<0.05 and 
** P<0.01. (C-E) PC3 cells stimulated with compound 1 as in (A) were stained with DAPI 
and rhodamine-phalloidin to label filamentous actin. DMSO was used as a control (0 
µM). Bar, 50 µm. The histogram in (D) shows the mean percentage of retracting cells. 
Cells having rounded shape and area less than 20% of the mean value obtained for the 
Fc stimulated cells were scored as retracting. The histogram in (E) shows the mean 
area of the cells normalized to the value obtained for the Fc stimulated cells. Bars in (D) 
and (E) indicate standard error from 3 experiments. (F-H) The same experiments as in 
(C-E) were performed using compound 5. 
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Compound 1 and compound 5 inhibit EphA4-mediated growth cone 
collapse in retinal neurons 
Growth cones extending from retinal explants are well known to collapse in 
response to ephrin stimulation (Drescher et al., 1995). EphA4 is 
homogenously expressed in different parts of the retina, while other EphA 
receptors are present in the temporal but not the nasal region (Connor et 
al., 1998). Therefore, EphA4 is the predominant EphA receptor expressed 
in the nasal retina. For this reason, nasal retinal explants were chosen to 
test whether the 2,5-dimethylpyrrolyl benzoic acid derivatives are able to 
counteract EphA4-mediated growth cone collapse after ephrin-A 
stimulation. In explants treated with the KYL peptide (Fig. 2.10A), 
compound 1 (Fig. 2.10B) or compound 5 (Fig. 2.10C), the growth 
collapsing effects of ephrin-A5 Fc were completely blocked. Neither the 
peptide nor the compounds had any effect on growth cone shape on their 
own. This is consistent with the recent report that the KYL peptide protects 
rat neocortical growth cones from collapsing after ephrin-A5 Fc treatment 
(Fabes et al., 2007). The KYL peptide has also been shown to promote 
axonal growth and functional recovery after corticospinal tract injury of the 
rat spinal cord (Fabes et al., 2007). The effect of the KYL peptide and the 2 
2,5-dimethylpyrrolyl benzoic acid derivatives on growth cones is an 
encouraging result, which suggests that they could be used to enhance 
axon regrowth after injury. 
 
Structure-activity relationship analysis of analogs of compounds 1  
and 5 
In order to find compounds related to compounds 1 and 5 but with higher 
potency, 56 compounds having the 2,5-dimethylpyrrolyl benzene scaffold or 
the ortho-hydroxybenzoic acid moiety were tested for inhibition of ligand 
binding to EphA4. The compounds were obtained from commercial sources 
or from the Medicinal Chemistry Facility of the Burnham Institute for Medical 
Research. The structures and IC50 values for inhibition of EphA4-KYL 
binding of some of the compounds tested are shown in Fig. 2.11.  
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Fig. 2.10. KYL peptide, compound 1 and compound 5 prevent ephrin-induced 
growth cone collapse in   retinal neurons. (A,B) Retina explants from E6 chicken 
embryos were preincubated with 5 µM of KYL peptide for 15 min, stimulated for 30 min 
with 1 µg/ml ephrin-A5 Fc, or Fc as a control, and stained with rhodamine-phalloidin. 
Approximately 30-80 growth cones were scored for each condition. The histogram in (B) 
shows the mean percentages of collapsed, partially collapsed and not collapsed growth 
cones. Growth cones were scored as “not collapsed” when lamellipodia or more than 3 
filopodia where present, as “collapsed” when no lamellipodia or filopodia were visible and 
as “partially collapsed” in the other cases. Bars indicate standard error from 2 independent 
experiments. (C-F) The same experiment as in (A) was performed, but retina explants 
were treated with Compound 1 (C-D) or 5 (E-F) at 400 µM. Approximately 80-250 growth 
cones were scored for each experiment and each condition. Bars in (D) indicate standard 
errors from measurements in 2 independent experiments and bars in (F) indicate standard 
errors from duplicate measurements in 1 experiment. Percent of collapsed growth cones 
in the different conditions were compared to the Fc control by one-way ANOVA and 
Newman-Keul’s post test. * P<0.05 
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Fig. 2.11. Structures of 2,5-dimethylpyrrolyl benzoic acid analogs and IC50 values in µM 
for inhibition of EphA4 AP binding to immobilized biotinylated KYL peptide. 
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Although many of the compounds showed inhibitory activity with the 
peptide, none of them inhibited EphA4-ephrin binding. Even introducing 
small changes to the structure abolished the ability to inhibit ephrin binding. 
Indeed, compounds lacking the hydroxyl group at position 2 on the benzene 
ring (compounds 19, 21); compounds having the carboxylic group in place 
of the hydroxyl group (compounds 24, 25) or the hydroxyl group in place of 
the carboxylic group on the benzene ring (compound 17); or compounds 
with the carboxylic group and the hydroxyl group placed at different 
positions in the benzene ring (compounds 14, 15) did not show any 
inhibition of EphA4-ephrin binding. These results suggest that the presence 
of the hydroxyl and carboxylic moieties and their position on the benzene 
ring are crucial for the activity of the compounds. This was also confirmed 
by the loss of inhibitory activity when the hydroxyl or carboxylic group in 
compound 1 was substituted with a chlorine atom (compounds 8, 18).  In 
addition, no inhibition was observed with the methyl-ester derivative of 
compound 1 (compound 16) or when a methoxy group (compound 26) was 
put in place of the carboxylic group in para position with respect to the 
pyrrole ring, suggesting that some hydrogen bonding at this position may be 
involved in the binding of the compounds to EphA4.  
Some alternatives to the 2,5-dimethyl pyrrolyl group were also tested. 
Eliminating or modifying the 2 methyl groups (compounds 11, 22) abolished 
the inhibitory activity with the ephrin and almost abolished the inhibitory 
activity with the KYL peptide in the case of compound 22, presumably 
because the methyl groups cause a rotation of the plane containing the 
pyrrole with respect to the plane containing the benzene ring, which may be 
important for the binding of the compound. Another possibility to explain the 
behavior of compound 22, which is inactive despite being very similar to the 
2 active compounds, is that the absence of the methyl group makes the 
pyrrole ring more unstable. However, this hypothesis was found to be 
incorrect based on the results obtained using compounds where the pyrrole 
ring was substituted with an adamantyl or isoindolyl group (compounds 9, 
20) or by 2 phenyl groups fused with the hydroxyl benzoic acid (compound 
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23). These compounds would be expected to be more stable than 
compounds with the pyrrole ring, but still do not inhibit EphA4 binding. 
Furthermore, inserting a bigger moiety, like a benzene ring (compound 10) 
in place of one of the methyl groups also abolished activity, probably by 
creating steric hindrance. 
Although the compounds that we screened did not detectably inhibit 
ephrin binding to EphA4 or EphA2, their IC50 values for inhibition of EphA4-
KYL peptide binding could be used as a guide to design modified versions 
of compounds 1 and 5 that might have increased potency. By comparing 
the IC50 values of compounds 7 and 19 and compounds 12 and 21, which 
only differ in a methyl group attached to the benzene ring, a 2-3 fold 
difference in the inhibitory activity can be observed. This suggests that 
adding a methyl group to the structure of the original compounds may 
improve EphA4-ephrin inhibition. In addition, compounds 2, 3, and 6, which 
have a phenoxy acetic acid, a phenyl acetic acid and a phenyl propanoic 
acid, in place of the benzoic acid, show a 10 to 40 fold decrease in the IC50 
values compared to compound 19, suggesting that exchanging the 
carboxylic group of compounds 1 and 5 with these other groups may 
significantly improve inhibitory activity. Although the concentrations of 
compounds 1 and 5 required to observe an effect are rather high, the 
properties of these compounds are very promising: they are specific for only 
2 out of the 16 Eph receptors, they behave like reversible competitive 
inhibitors and they show activity in cell-based and functional assays without 
showing any toxicity. Therefore, the improvement of the potency that the 
described structural modifications could achieve would make this class of 
compounds a promising lead to develop pharmaceuticals for the treatment 
of EphA4- and EphA2- mediated pathologies.  
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Chapter 3 
 
Platinum(II) tetraamines as potential inhibitors  
of the EphA2 receptor 
 
ABSTRACT 
Angiogenesis is a crucial process involved in normal development as well 
as in many diseases, such as cancer. Being overexpressed in many types 
of cancer and in tumor vasculature, the EphA2 receptor tyrosine kinase is a 
promising new target for inhibition of tumor angiogenesis and other forms of 
pathological angiogenesis. Some peptide inhibitors and monoclonal 
antibodies that inhibit EphA2 activity have shown to inhibit receptor-ligand 
interaction and decrease tumor angiogenesis and progression in vivo, but 
no chemical compound inhibitors, which would have more desirable 
pharmaceutical properties, have been identified so far. Here we report the 
screen of combinatorial libraries for inhibition of EphA2-ephrin binding and 
the identification of platinum(II) tetraamine compounds as potential 
therapeutics.  
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INTRODUCTION 
Angiogenesis is a highly complex process that plays critical roles in normal 
development as well as in multiple pathological processes, including tumor 
neovascularization, ischaemic recovery after infarction (Schumacher et al., 
1998), development of the advanced arterosclerotic plaque (Hughes, 1996), 
retinopathy (Steinle et al., 2003) and wound healing (Li et al., 2003). 
Several growth factors and their receptors are involved in the angiogenic 
process, including the Eph receptor tyrosine kinases. This family of 
receptors and their ligands, the ephrins, are well known regulators of 
vascular remodeling in the embryo, and more recent evidence also 
associates them with post-natal angiogenesis and pathological forms of 
angiogenesis. 
EphA2 is a member of the A class of Eph receptors and it is activated 
by binding to the 6 GPI-linked ephrin-A ligands. This receptor, previously 
known as Eck, for epithelial cell kinase, was originally identified in a screen 
for tyrosine kinases expressed in epithelial cells (Lindberg and Hunter, 
1990) and was subsequently characterized as an important player in the 
angiogenic response in the adult using the corneal angiogenesis assay 
(Pandey et al., 1995). Inflammatory cytokines such as tumor necrosis factor 
alpha (TNFα) stimulate EphA2 activity through the upregulation of ephrin-
A1 expression in endothelial cells. Furthermore, EphA2 is required for 
endothelial capillary tube formation in vitro (Ogawa et al., 2000), and 
promotes the formation of blood vessel-like structures by melanoma cells 
(Hess et al., 2001). The angiogenic effect of EphA2 involves the activation 
of the Rho-family GTPase Rac by phosphatidylinositol 3-kinase (Brantley-
Sieders et al., 2004). EphA2 expression seems to be restricted to adult 
angiogenic blood vessels, since this receptor is not expressed in quiescent 
blood vessels or in embryonic vasculature (McBride and Ruiz, 1998; Ogawa 
et al., 2000). Consistent with this observation, EphA2 knock-out mice show 
defective angiogenic responses in the adult, without showing any obvious 
defect during development (Brantley-Sieders et al., 2004; Brantley-Sieders 
et al., 2006). Ephrin-A1 is also not present in adult quiescent blood vessels, 
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although it has been detected in the embryonic vasculature (McBride and 
Ruiz, 1998). The differential expression of EphA2 suggests that targeting 
the pathological effects of EphA2 would not affect the normal vasculature.  
EphA2 and ephrin-A1 appear to also play an important role in tumor 
development, since they are overexpressed in numerous types of cancer, 
including breast, cervix, colon, esophagus, lung, ovary, prostate, kidney 
carcinomas and melanoma (Ireton and Chen, 2005). The level of EphA2 
expression often correlates with the malignancy of the tumor and with poor 
patient outcome. EphA2 and ephrin-A1 are expressed both in the tumor 
cells, where the receptor localization also seems to be altered (Ireton and 
Chen, 2005) and in the tumor vasculature (Brantley et al., 2002; Ogawa et 
al., 2000). The mechanism of action of EphA2 and ephrin A1 in tumors is 
not well understood, but presumably ephrin-A1 expressed in tumor 
endothelial cells and in tumor cells acts as a pro-angiogenic factor by 
interacting with EphA2 expressed in tumor endothelial cells. 
Supporting this hypothesis, blocking the activation of EphA2 with 
soluble recombinant EphA2 (EphA2 Fc) inhibits angiogenic response and 
counteracts the effect of proangiogenic factors as TNF-α and VEGF 
(Brantley et al., 2002; Cheng et al., 2003; Cheng et al., 2002; Dobrzanski et 
al., 2004; Pandey et al., 1995). The decreased angiogenesis influences 
tumor growth, which is also reduced due to the lack of oxygen and 
nutrients. Consistent with the idea that the observed diminished tumor 
growth is a secondary effect of decreased angiogenesis, soluble EphA Fc 
receptors show no effect on growth and survival of tumor cells in culture 
(Cheng et al., 2003). Similar reduction of tumor size and vascularization is 
also observed when the EphA2 gene is inactivated (Brantley-Sieders et al., 
2006) or when monoclonal antibodies are used to stimulate EphA2 
endocytosis and degradation (Carles-Kinch et al., 2002).  
Two peptides have also been identified, which selectively bind to the 
EphA2 receptor. Despite being apparently monomeric, these peptides 
stimulate EphA2 phosphorylation in cells through unknown mechanisms 
(Koolpe et al., 2002). Recent work has shown that the knockdown of EphA2 
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in the retina by antisense nucleic acids reduces retinal neovascularization 
(Shen et al., 2007). This effect could be exploited for the treatment of 
diseases characterized by abnormal vascularization, such as retinopathy.  
The results described above show how targeting EphA2 could be 
useful for the treatment of cancer and other forms of pathological 
angiogenesis. However, inhibitors with better pharmacological properties 
compared to the large molecules that have been used so far would be 
desirable. 
Mixture-based synthetic combinatorial libraries have emerged in the 
last few years as a valuable tool for the identification of compounds that 
show activities in a variety of systems. Combinatorial libraries allow the 
testing of millions of compounds without requiring classical high throughput 
means and have been shown to work in many different assays (Houghten 
et al., 1999). We tested mixture-based combinatorial libraries in a screening 
for inhibitors of EphA2 and we identified platinum(II) tetraamine mixtures as 
promising molecules for EphA2 specific targeting.  
 
MATERIALS AND METHODS 
Mixture-based combinatorial library screen for EphA2 inhibitors 
A 96-well format ELISA assay was used for the screening of a sampler of 
30 libraries of compounds obtained from the Torrey Pines Institute for 
Molecular Studies (La Jolla, CA). Protein A-coated plates (Pierce 
Biotecnology, Rockford, IL) were incubated with 1 µg/ml of ephrin-A1 Fc or 
ephrin-A5 Fc diluted in binding buffer (Tris-buffered saline (TBS) (150 mM 
NaCl, 50 mM Tris-HCl, pH 7.5) containing 1 mM CaCl2 and 0.01% Tween 
20). The mixtures, which were dissolved in dimethylformamide (DMF), were 
then added at a concentration of 100 µg/ml together with cell culture 
medium containing the ephrin-binding domain of EphA2 fused with alkaline 
phosphatase (EphA2 AP) diluted 1:10 in binding buffer. The mixtures were 
incubated for 3 hours at room temperature before adding p-
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nitrophenylphosphate (pNPP) (Pierce Biotecnology, Rockford, IL) as a 
substrate and measuring the absorbance at 405 nm. Alkaline phosphatase 
activity from wells where Fc was added instead of ephrin Fc-fusion proteins 
was subtracted as the background. The inhibitory activity of the mixtures 
was calculated by dividing the absorbance observed in the presence of 
each mixture and the absorbance from wells where only DMF was added.  
 
Synthesis of tetraamine and platinum(II) tetraamine libraries 
Tetraamine libraries were prepared using the “tea bag” method for 
simultaneous multiple synthesis (Houghten et al., 1999). Resin-bound 
mixtures were synthesized using ratios of amino acids previously 
determined in order to have equimolar ratios (Ostresh et al., 1994). A 
tripeptide bound to a 4-methylbenzhydrylamine hydrochloride salt (MBHA) 
resin was used as starting material. The tripeptide combinatorial sub-
libraries were prepared in the positional scanning format using the “reagent 
mixture method” (Ostresh et al., 1994) and 58 different amino acids. The 
obtained tripeptides were exhaustively reduced by a 72 hour treatment with 
BH3-THF at 65°C, followed by overnight treatment with neat piperidine at 
65°C (Ostresh et al., 1998). Resin-bound mixtures were cleaved using 
hydrogen fluoride procedures (Houghten et al., 1996) and were extracted 
using 95% acetic acid. Synthetic combinatorial libraries were lyophilized 
and reconstituted in DMF at 10 mg/ml. Platinum(II) tetraamine mixtures 
were synthesized from tetraamine combinatorial libraries by solution-phase 
interaction with K2PtCl4, as previously described. (Nefzi et al., 2006). 
Individual compounds were prepared using the methods described above 
and their purity and identity were characterized by reverse phase HPLC and 
laser desorption mass spectrometry. Some libraries were filtered using 0.75 
µm MWCO pore size filters in order to remove any traces of free platinum 
present in the platinum(II) tetraamine mixtures. 
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Platinum(II) tetraamine inhibition of EphA2-ephrin-A binding  
The ability of the tetraamine and platinum(II) tetraamine mixtures and single 
compounds to inhibit EphA2 interaction with ephrin-A1 or ephrin-A5 was 
assessed as described above. Different concentrations of the mixtures of 
compounds were added to plates coated with protein A and ephrin-A 
ligands, together with EphA2 AP. As a control for non-specific inhibition of 
protein-protein interactions or alkaline phosphatase activity, a modified 
ELISA assay was performed. High binding capacity plates were coated 
overnight at 4°C with an anti-human IgG conjugated with AP (Promega, 
Madison, WI) diluted to 0.1 µg/ml in borate buffer 0.1 M pH 8.7. Compounds 
were then added for 3 hours, before adding pNPP as the substrate and 
measuring the absorbance at 405 nm. Absorbance from wells where no 
anti-human IgG-AP was added was subtracted as background. 
 
RESULTS AND DISCUSSION 
Platinum(II) tetraamine libraries inhibit ephrin binding to EphA2 
Mixture-based combinatorial libraries are mixtures of compounds having the 
same structural scaffold but different functional groups at some variable 
positions (indicated by R). The higher the number of variable positions in 
the molecule and the number of functionalities used for the synthesis of the 
mixture, the higher the complexity of the mixture. Each library can contain 
thousands or even millions of compounds, which can be screened using a 
“low throughput” approach. 
A sampler of 30 mixture-based combinatorial libraries of compounds 
having different structural scaffolds was tested for inhibition of EphA2 
binding to ephrin-A1 or ephrin-A5 (Fig. 3.1). The libraries contained 2 to 4 
variable positions, each corresponding to a mixture having all but one 
defined functional groups. In total, 91 mixtures were screened. The most 
effective at inhibiting EphA2-ephrin interaction, at a concentration of 100 
µg/ml, were the three mixtures corresponding to the platinum(II) tetraamine 
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scaffold (mixtures 89-91), which showed an average inhibition of 18% and 
50% with ephrin-A1 and ephrin-A5, respectively (Fig. 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These compounds consist in a tetraamine scaffold, which is derived 
from exhaustive reduction of a tripeptide, with a platinum atom coordinated 
at the center of the molecule. Three variable positions (R1, R2 and R3) are 
present (Fig 3.2A). Controls verified that the platinum(II) tetraamine libraries 
do not inhibit alkaline phosphatase activity or the pre-formed protein A-Fc 
complexes (data not shown). Interestingly libraries 86-88, which contain 
tetraamines having the exact same structure as the platinum(II) tetraamines 
but without the metal, exhibited substantial lower activity when tested with 
ephrin-A5, suggesting that coordination of the central platinum is important 
for the inhibitory activity of these complexes. The results obtained with the 
Fig. 3.1. Screening of positional scanning combinatorial libraries for inhibition of 
EphA2-ephrin-A binding. Ninety-one mixtures at 100 µg/ml were added together with 
EphA2 AP to ELISA plates precoated with protein A and ephrin-A1 or ephrin-A5. 
Percentage inhibition of EphA2 binding to the ephrins is shown. Averages from 2 
independent experiments ± SE are shown. 
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two ephrin ligands were qualitatively similar. However, EphA2 binding to 
ephrin-A5 was more easily inhibited by the platinum(II) tetraamine 
complexes and less easily by the metal-free tetraamine compared to EphA2 
binding to ephrin-A1. Furthermore, the platinum(II) tetraamine libraries 
appear to be selective for EphA2. Indeed when they were tested for 
inhibition of ephrin binding to two related Eph receptors, EphA4 and EphB4, 
no activity was observed (Fig. 3.2B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positional scanning screen of the platinum (II) tetraamine libraries 
The platinum(II) tetraamine library was synthesized in the positional 
scanning format (Houghten et al., 1999). Positional scanning synthetic 
combinatorial libraries are composed of one sublibrary for each variable 
position, each further divided into mixtures having a different functional 
group at that variable position.  
 
 
 
Fig. 3.2. The platinum(II) tetraamine library selectively inhibits binding of  EphA2 to 
ephrin-A ligands. (A) Platinum(II) tetraamine scaffold. (B) EphA2 AP, EphA4 AP and 
EphB4 AP were incubated on ELISA plates coated with ephrin-A1 Fc, ephrin-A5 Fc or 
ephrin-B2 Fc, respectively. (-) Indicates that DMF was added in place of the libraries as a 
control; (+) indicates that the R1 platinum(II) tetraamine sub-library mixture was added at 
100 µM/ml together with the Eph receptor AP fusion proteins. Averages from 3 
measurements ± SE are shown.  
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Fig. 3.3. Positional scanning mixtures of the platinum(II) tetraamine library inhibit 
EphA2-ephrin-A interaction. (A-B) The platinum(II) tetraamine mixtures were screened 
at 50 µg/ml (A) or 100 µg/ml (B) for inhibition of EphA2 AP binding to ephrin-A1 (black) or 
ephrin-A5 (blue) immobilized on ELISA plates. The histograms show averages from 2 
independent experiments ± SE. (C) The tetraamine mixtures were screened at 100 µg/ml 
for inhibition of EphA2 binding to ephrin-A1 (black) or ephrin-A5 (blue). Percent inhibition 
of EphA2 binding to ephrins is shown in all the panels. Pt(II), platinum(II). 
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Each compound present in a given mixture has an individual building block 
at a given variable position and mixtures of all the building blocks used for 
the synthesis of the library at the other variable positions. The sublibraries 
for each position contain the same individual compounds, but they differ by 
the location of the variable position. For the synthesis of the platinum(II) 
tetraamine libraries 58 functional groups were used, therefore 58 mixtures 
were present for each variable position, each one containing 3,364 
individual compounds. The mixtures corresponding to the R1 position, 
having defined functionalities at the R1 position and mixtures of functional 
groups at the R2 and R3 positions, were screened at a concentration of 50 
µg/ml (Fig. 3.3A) and 100 µg/ml (Fig. 3.3B) using either ephrin-A1 or 
ephrin-A5. This second screen confirmed that the platinum(II) tetraamine 
libraries contain compounds able to inhibit EphA2-ephrin interaction and 
that the extent of the inhibition depends on the concentration of the 
compounds and on the functional group present at the variable position. As 
observed in the initial screen, the results obtained with ephrin-A1 and 
ephrin-A5 were qualitatively similar, with a higher inhibition level observed 
using ephrin-A5. The 58 R1 positional scanning mixtures of the tetraamine 
library were also screened (Fig 3.3C). The extent of inhibition was 
significantly lower, particularly in the case of ephrin-A5, confirming that the 
presence of platinum is crucial for the activity of these compounds, 
presumably by conferring a specific three-dimensional conformation.   
The R2 and R3 positional scanning mixtures containing platinum(II) 
tetraamines were then screened at 100 µg/ml in order to complete the 
positional scanning analysis of the library (Fig 3.4). Only few of the mixtures 
showed substantial inhibition, suggesting that only few of the compounds 
present in each mixture account for the observed activities.  
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Fig. 3.4. Screen of 3 positional scanning platinum(II) tetraamine mixtures. EphA2 
binding to ephrin-A1 (black) or ephrin-A5 (blue) was measured in the absence or in the 
presence of platinum(II) tetraamine mixtures added at 100 µg/ml. Mixtures corresponding to 
R1, R2 and R3 positions were tested. R1 is the same as B in Fig. 3. Averages from 2 
experiments ± SE are shown 
 
 Chapter 3 
 64 
Table 3.I. IC50 values for inhibition of EphA2-ephrin-A1 interaction by platinum(II) 
tetraamine mixtures and mixtures chosen for the synthesis of individual compounds (blue = 
R1 position, yellow = R2 position;  green = R3 position) 
 
 
Mixture Variable position Functional group IC50 (µM) 
6 R1 Boc-L-Ile >300 
7 R1 Boc-L-Lys(CBZ) 110 
11 R1 Boc-L-Gln >300 
12 R1 Boc-L-Arg(Tos) 47 
14 R1 Boc-L-Thr(Bzl) 150 
23 R1 Boc-D-Lys(CBZ) >300 
25 R1 Boc-D-Asn 67 
27 R1 Boc-D-Gln 65 
28 R1 Boc-D-Arg(Tos) 31 
33 R1 Boc-D-Tyr(BrZ) 48 
37 R1 Boc-D-Norleucine 79 
38 R1 aN-CBZ-L-Lysine(Boc) 67 
52 R1 Boc-D-4-Chlorophenylalanine 58 
53 R1 Boc-L-4-Fluorophenylalanine 48 
54 R1 Boc-D-4-Fluorophenylalanine 52 
58 R1 Boc-O-ethyl-D-Tyrosine 130 
59 R2 Boc-L-Ala 210 
70 R2 Boc-L-Arg(Tos) 90 
82 R2 Boc-D-Leu 68 
83 R2 Boc-D-Asn 38 
85 R2 Boc-D-Gln 60 
87 R2 Boc-D-Ser(Bzl) 50 
95 R2 Boc-D-Norleucine 86 
128 R3 Boc-L-Arg(Tos) 86 
132 R3 Boc-L-Trp(CHO) 260 
151 R3 Boc-D-Norvaline 160 
152 R3 Boc-L-Norleucine 120 
155 R3 Boc-L-Ornithine(CBZ) 160 
156 R3 aN-CBZ-L-Ornithine(Boc) 160 
171 R3 Boc-L-a-tButylglycine 170 
 
 
Synthesis of individual platinum(II) tetraamines 
The positional scanning screen revealed an activity profile, which was used 
to guide the deconvolution approach. The concentration dependence of the 
inhibition of EphA2-ephrin-A1 interaction for the most active compounds 
was determined (Table 3.I). Taking into account the obtained IC50 values 
and the results from the positional scanning screening, 11 functional groups 
were chosen for the synthesis of individual compounds: 5 for the R1 
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position and 3 for each of the R2 and R3 positions (Table 3.I). Compounds 
with all the possible combinations of the chosen functional groups were 
synthesized and tested for inhibition of EphA2-ephrin-A1. Among the 45 
individual compounds tested only 4 showed some inhibition, with IC50 value 
comprised between 140 and 260 µg/ml, values much higher than what 
expected from the results obtained in the positional scanning screening. It is 
possible that functional groups singularly active at one of the variable 
positions are not as active when combined together. Indeed, the activity of a 
mixture is due to the presence of specific active compounds and not to the 
functional groups as separate independent entities. 
 
Iteration of the platinum (II) tetraamine libraries 
Another deconvolution method that can be used is the iterative method, 
which consists in fixing one of the variable positions with the functional 
group corresponding to the most active mixture, while testing all the 
functional groups at the other positions. The process is repeated 
sequentially until all the positions are defined. A significant improvement in 
the activity should be observed upon defining each additional position. This 
method requires more steps compared to the positional scanning method, 
but allows the screening of all the sublibraries associated with one particular 
group.  
The iterative deconvolution method was applied to the platinum(II) 
tetraamine library. Since the higher activity had been observed with the 
mixture corresponding to the R1 position, the first fixed position was R1. 
The synthesis of mixtures containing L-Arg at the R1 position, one of the 58 
building blocks at the R2 position and mixture of all building blocks at the 
R3 position was performed in parallel with the synthesis of the original sub-
library containing L-Arg at the R1 position and mixtures of functional groups 
at the R2 and R3 positions, as a control. The results of the screening of the 
iteration mixtures are shown in Fig. 3.5. Although the mixtures tested at 100 
µg/ml showed inhibition of EphA2-ephrin-A1 binding, the activity was not 
greatly improved compared to the previously tested mixtures having the R2 
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position defined (compare to Fig. 3.4, second panel). In addition, there was 
no clear differentiation among the mixtures, since 38 mixtures showed 
inhibition comprised between 20 and 50%. It is possible that the lack of 
differentiation is due to the fact that the presence of the L-Arg at the R1 
position confers a certain degree of activity to the compounds regardless of 
the chemical group present at the other positions. However, some 
differentiation could be observed in the activities of the mixtures tested at 50 
µg/ml, differentiation that will guide the synthesis of the individual 
compounds for the next step of the iterative deconvolution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 3.5. Screen of iteration platinum(II) tetraamine mixtures. EphA2 binding to ephrin-
A1 was measured in the absence or in the presence of L-Arg iteration platinum(II) 
tetraamine mixtures added at 100 or 50 µg/ml. C represents the re-synthesis of the 
mixture having L-Arg at the R1 position and mixture of functional groups at the R2 and R3 
positions. Eleven mixtures were filtered in order to remove any traces of free platinum and 
retested. The same results as before the filtration were obtained for all the mixtures 
except the C sample. For this sample the inhibition after filtration is shown. Averages from 
2 measurements ± SE are shown. Pt(II), platinum(II). 
 Chapter 3 
 67 
Is has to be noted that 2 of the 3 functionalities previously chosen for 
the synthesis of single compounds, D-Leu and D-Asn, which correspond to 
mixtures 24 and 25, showed no activity in the iteration mixtures screen, 
explaining why the single compounds having these chemical moieties at the 
R2 position and L-Arg at the R1 position did not inhibit EphA2-ephrin 
binding. However, the presence at the R2 position of L-Arg (mixture 12), 
which was also used for the synthesis of the individual compounds, confers 
activity, suggesting that the group present at the third position is crucial for 
the activity of these compounds. In addition to the synthesis of individual 
compounds, the synthesis of other 2 iteration libraries will be carried out, 
using 2 functional groups in order to compare their activities in the next 
iteration step. D-Arg and D-Tyr will be used in this synthesis, in order to 
compare the effect of different amino acid chirality and different substituents 
and therefore identify the functional groups responsible for the activity of the 
platinum(II) tetraamine library. 
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Chapter 4 
 
Targeting the EphB4 receptor in cancer with TNYL-RAW, 
an antagonistic peptide 
 
ABSTRACT 
The Eph receptors are a family of tyrosine kinases involved in many 
pathological processes and have emerged as promising drug target 
candidates. EphB4 in particular is overexpressed in many types of cancer 
and inhibition of the interaction with its ligand, ephrin-B2, could be useful for 
the treatment of cancer and for inhibiting tumor angiogenesis and other 
forms of pathological angiogenesis. The TNYN-RAW 15-mer peptide is a 
potent and specific antagonist of EphB4 and could, therefore, be exploited 
in the treatment of pathologies involving the receptor. However, unmodified 
peptides are rapidly lost in vivo due to a variety of processes, including 
proteolytic degradation, instability and clearance through the kidney and the 
reticuloendothelial system. Coupling to polyethylene glycol (PEG) 
molecules or to the Fc portion of human IgG1 has been shown to reduce 
these processes, thus increasing the stability and the circulating half-lives of 
peptides. Here we describe the synthesis of PEGylated and Fc fused forms 
of the TNYL-RAW peptide and analyze the effects of such modifications on 
the binding properties of TNYL-RAW, its stability in cell conditioned medium 
and its retention in the mouse blood. Our results show that PEGylation and 
fusion to Fc improve the pharmacological properties of the peptide. 
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INTRODUCTION 
The Eph receptors comprise a large family of tyrosine kinase receptors 
involved in a multitude of biological processes, both in developing and adult 
tissues. Besides their role in a variety of physiological functions, the Eph 
receptors have been implicated in different pathological processes, 
including cancer progression and metastasis (Dodelet and Pasquale, 2000; 
Nakamoto and Bergemann, 2002), pathological forms of angiogenesis 
(Brantley-Sieders and Chen, 2004), inhibition of spinal cord regeneration 
after injury (Goldshmit et al., 2004) and human congenital malformations 
(Twigg et al., 2004; Wieland et al., 2004). Therefore, inhibition of Eph-ephrin 
interaction could be useful for diverse medical application. Given the variety 
of processes mediated by this class of receptors, however, high specificity 
is desirable in order to inhibit the pathological effects of a specific Eph 
receptor without affecting the physiological functions of the other closely 
related receptors. 
 Despite the promiscuity observed for Eph receptors-ephrin 
interactions (see Chapter 1), several peptides that selectively target only 
one of the Eph receptors and inhibit ephrin binding have been identified 
(Koolpe et al., 2005; Koolpe et al., 2002; Murai et al., 2003). The most 
potent peptide identified so far is TNYL-RAW, which targets EphB4 (Koolpe 
et al., 2005). The TNYL-RAW peptide, a 15 amino acid long peptide 
identified by phage display, shows a remarkably high binding affinity for 
EphB4 (with a KD of 1-2 nM). This affinity is comparable to that of ephrin-
B2, the preferred ligand for EphB4. TNYL-RAW binds in the hydrophobic 
binding cleft that constitutes the high affinity binding site for ephrin-B2. 
Surprisingly, given that the peptide and ephrin-B2 contain four identical 
consecutive amino acids, the conformation and orientation of TNYL-RAW in 
the EphB4 binding pocket is distinct from that of the ephrin-B2 G-H loop, 
which binds in the same position (Chrencik et al., 2006)  
 The EphB4-ephrin-B2 interaction is known to play a critical role in 
blood vessel remodeling during embryonic development (Adams et al., 
1999; Foo et al., 2006) and more recent evidence also shows its 
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involvement in cancer angiogenesis and other forms of pathological 
angiogenensis (Dodelet and Pasquale, 2000; Masood et al., 2005; 
Nakamoto and Bergemann, 2002; Noren et al., 2004; Walker-Daniels et al., 
2003). EphB4 is upregulated in prostate, colorectal, lung, ovarian and 
breast cancer and in mesothelioma (Berclaz et al., 2003; Liu et al., 2002; 
Xia et al., 2005; Xia et al., 2006), consistent with a role in tumor 
development and progression. However, little is known about the 
mechanism of action of this receptor in the oncogenic process. EphB4 
expressed in the tumor cells has been shown to stimulate tumor 
angiogenesis by activating ephrin-B2 reverse signal in the surrounding 
blood vessels (Noren et al., 2004). EphB4 is also present in endothelial 
cells, where it promotes tumor angiogenesis by stimulating ephrin-B2 
reverse signaling (Erber et al., 2006). As suggested by this evidence, 
interfering with EphB4-ephrin-B2 interaction decreases tumor angiogenesis 
and tumor growth. Indeed, a soluble monomeric form of EphB4, which 
blocks EphB4-ephrin-B2 bidirectional signaling, inhibits capillary sprouting 
in cultured endothelial cells and decreases the growth of breast tumors and 
other types of tumor xenografts in mice (Kertesz et al., 2006; Martiny-Baron 
et al., 2004). A soluble form of EphB4, as well as a soluble form of ephrin-
B2, also inhibits neovascularization in a model of retinophaty (Zamora et al., 
2005). Recent evidence also shows that the inhibition of EphB4-ephrin-B2 
signals in cultured melanoma cells decreases the invasiveness of these 
cells (Meyer et al., 2005; Yang et al., 2006). 
 TNYL-RAW, which inhibits EphB4 activation in breast cancer cells 
(Koolpe et al., 2005) and blocks capillary-like tube formation in HUVE 
endothelial cells in culture (Salvucci et al., 2006), is a good drug candidate 
for the treatment of EphB4-mediated diseases. However, unmodified 
peptides are known to have a short life in cell-culture or when systemically 
administered in vivo (Ladner et al., 2004; Torchilin and Lukyanov, 2003). 
Peptides are rapidly degraded by proteases in biological fluids, cleared 
through the reticuloendothelial system or filtered by the kidneys. 
Polyethylene glycol (PEG) covalent coupling has been shown to improve 
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the pharmacodynamic and phamacokinetic properties of drugs. Indeed, 
PEG-conjugated biomolecules show increased stability, higher solubility, 
lower clearance and better surface shielding from antigen-recognizing cells, 
antibodies and proteolitic enzymes, which result in longer in vivo circulating 
half-lives (Hamidi et al., 2006; Harris et al., 2001). Another approach to 
improve the peptide stability and retention in the blood circulation is the 
fusion with the Fc part of human IgG1 (Kim et al., 1998) . Numerous 
molecules have been coupled to the immunoglobulin Fc domain, showing 
retention of their biological activity and increased circulating half-lives. This 
is at least in part due to the ability of Fc to bind to FcRn, the neonatal Fc 
receptor, which protects the molecules bound to it from catabolism 
(Junghans and Anderson, 1996). 
 In this study we describe the conjugation of the TNYL-RAW peptide 
with 10 or 40 kDa PEG molecules or with the Fc portion of human IgG1. We 
then analyze the effect of these modifications on the binding capacity, 
stability in cell culture medium and retention in the mouse blood circulation 
of the peptide. 
 
MATERIALS AND METHODS 
Reagents 
The TNYL-RAW peptide was synthesized with a carboxy-terminal 
aminoexanoic acid linker with biotin attached to a lysine side chain and was 
obtained from the Protein Facility of the Burnham Institute for Medical 
Research. Activated monofunctional polyethylene glycol molecules, PEG-
succinimydil-α-methybutanoate ((SMB)-PEG, MW~10 kDa) and PEG- 
succinimidyl-glutarate (NHS-glutaryl PEG, branched molecule, MW~40 
kDa)) were obtained from Nektar Therapeutics (San Carlos, CA) and NOF 
Corporation (Tokyo, Japan), respectively. The anti-PEG antibody AGP3 
was purchased from Academia Sinica, Taiwan. The secondary horseradish 
peroxidase (HRP)- conjugated anti-mouse IgG was from Morphosys 
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(Munich, Germany). The Fc fusion-proteins were obtained from R&D 
Systems, (Minneapolis, MN).  
 
PEGylation of the TNYL-RAW peptide 
TNYL-RAW peptide in phosphate buffer saline (PBS) at a concentration of 
200 to 500 µM was mixed with activated PEG molecules, which were also 
dissolved in PBS at a concentration between 2.7 and 11 µM. Either the 10 
kDa (SMB)-PEG or the 40 kDa branched NHS-glutaryl PEG were used, at 
different molar ratios to the peptide. The mixture was incubated for 30 min 
at room temperature, followed by overnight incubation at 4°C. The reactions 
were then dialyzed for 2 days at 4°C against PBS using 5,000 MWCO 
microdialysis units (Pierce Biotecnology, Rockford, IL), in order to remove 
the uncoupled peptide. PEGylation efficiency was analyzed by measuring 
absorbance at 280 nm. 
 
TNYL-RAW fused with human Fc 
cDNA encoding the TNYL-RAW peptide was cloned into a pcDNA3-based 
vector preceded by a signal sequence for secretion into the medium and 
followed by a GSGSK linker and human Fc. The DNA was used to transfect 
embryonic kidney HEK293 cells, which were then grown for 4 days in 
DMEM with 10% FBS before collecting the cell supernatant. TNYL-RAW Fc 
was purified using protein A coupled to sepharose beads (GE Healthcare, 
UK).  
 
Peptides binding to EphB4 
After immobilizing the EphB4-Fc fusion protein to protein A-coated wells 
(Pierce Biotecnology, Rockford, IL), TNYL-RAW or TNYL-RAW-PEG were 
added at different concentrations in binding buffer (Tris-buffered saline 
(TBS) (150 mM NaCl; 50 mM Tris-HCl, pH 7.5) with 1mM CaCl2 and 0.01% 
Tween 20). Horseradish peroxidase (HRP)-conjugated streptavidin diluted 
1:1,000 in binding buffer was then added, and the absorbance at 405 nm 
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was measured after 1 hour using 2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) (Sigma-Aldrich, Steinheim, Germany) in citric acid as 
a substrate. In the case of TNWL-RAW coupled with the 40 kDa NHS-
glutaryl PEG, which could not be detected using streptavidin-HRP, Ni-NTA 
coated plates (Qiagen, Valencia, CA) were used to immobilize EphB4 Fc 
(which also contains an hexa-histidine tag) and the bound PEGylated 
peptide was detected using 1.5 µg/ml AGP3 anti-PEG antibody in binding 
buffer, followed by 0.5 µg/ml secondary anti-mouse IgM-HRP. The 
absorbance from wells where no peptide was added was subtracted as the 
background and the data were analyzed using non linear regression. 
 As an alternative, protein L-coated plates (Pierce Biotecnology, 
Rockford, IL) were incubated with AGP3 antibody followed by the 
PEGylated peptide. Five µl of cell culture medium containing EphB4 alkaline 
phosphatase fusion protein (EphB4 AP) diluted 1:10 in binding buffer were 
then added. Bound EphB4 AP was detected using p-nitrophenylphosphate 
(pNPP) (Pierce Biotecnology, Rockford, IL) as a substrate by measuring the 
absorbance at 405 nm. 
For the detection of TNYL-RAW Fc binding to EphB4, protein A-
coated plates were incubated with 0.03 µg/well TNYL-RAW Fc or ephrin-B2 
Fc, and different amounts of EphB4 AP were then added. Absorbance was 
measured at 405 nm. Human Fc was used as a negative control.  
 
Inhibition of EphB4-ephrin-B2 binding 
Protein A-coated plates were used to immobilize ephrin-B2 Fc fusion 
protein. TNYL-RAW, TNYL-RAW-PEG and TNYL-RAW Fc at different 
concentrations were incubated for 3 hours with EphB4 AP culture medium 
diluted 1:10 in binding buffer and the amount of bound AP fusion protein 
was quantified by adding pNPP as the substrate and measuring the 
absorbance at 405 nm. Alkaline phosphatase activity from wells where 
human Fc was added instead of EphB4 Fc was subtracted as the 
background.  
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Measurement of alkaline phosphatase activity 
Cell culture medium containing placental alkaline phosphatase (PLAP) 
fusion proteins was incubated for 10 min at 60°C in order to inactivate 
endogenous alkaline phosphatases. Different amounts of conditioned 
medium were incubated at 37°C with the pNPP substrate. Alkaline 
phosphatase fusion proteins concentration was calculated from the linear 
regression of the absorbance measured at 405 nm plotted versus the 
amount of conditioned medium, assuming that the activity of PLAP is 1,500 
U/mg and that 1 mU causes a 0.04 increase in the absorbance at 405 nm at 
37°C.   
 
Detection of  TNYL-RAW in cell culture medium 
PC3 prostate cancer cells were grown overnight in RPMI 1640 medium 
(Mediatech, Inc, Herndon, VA) with 10% fetal bovine serum (FBS) (Hyclone, 
Logan, UT) and Pen/Strep. Biotinylated TNYL-RAW or TNYL-RAW-PEG 
peptides were added to the cells at a concentration of 1 µM for different 
times. The medium was collected and the peptide present in it was captured 
using neutravidin-coated plates (Pierce Biotecnology, Rockford, IL) and 
detected using EphB4 AP and pNPP substrate. The same experiment was 
also performed after replacing the cell medium with fresh medium just 
before the addition of the peptides or by adding to the cell medium protease 
inhibitors (10 µg/ml aprotinin, 5 µg/ml pepstatin and 10 µg/ml leupeptin) 
mixed together or added individually. In another format of the experiment, 
TNYL-RAW peptide or TNYL-RAW-PEG were added to the PC3 cell 
conditioned medium removed from the cells and the peptide was incubated 
for different times at 37°C. The same experiments were also carried out 
using C6 glioma cells grown overnight in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Irvine Scientific, Santa Ana, CA) with 10% FBS, 
Pen/Strep and Sodium Pyruvate and BPH1 prostate epithelial cells grown in 
DMEM/F-12 with 5% FBS.  
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Retention of TNYL-RAW peptide in mouse blood 
TNYL-RAW and TNYL-RAW-PEG were administered to mice by 
intravenous injection diluted in sterile PBS at a concentration of 40 µM in a 
150 µl volume. Blood was collected from the mouse orbital sinus 30 min or 
2 hours after injection and by cardiac puncture 6 hours after injection. Blood 
was kept at 4°C for few hours and then centrifuged for 30 min at 5,000 rpm 
at 4°C in order to isolate the serum, which was then stored at -20°C. TNYL-
RAW and TNYL-RAW-PEG binding to EphB4 was measured by ELISA 
assay as described above, using wells without peptide but with the same 
amount of mouse serum as the background. 
 
RESULTS AND DISCUSSION 
TNYL-RAW stability in cell culture medium 
Peptides have short half-lives in biological fluids, due to diverse processes, 
including proteolitic degradation. The stability of the TNYL-RAW peptide in 
PC3 prostate cancer cell conditioned medium was tested, confirming that 
the peptide is rapidly lost (Fig. 4.1A). The kinetics of peptide loss depend 
on the cell density and on the amount of time the culture medium remained 
in contact with the cells. Indeed, replacing the culture medium with fresh 
medium just before addition of the peptide slows down the degradation of 
the peptide, which remains intact for several hours (Fig 4.1B). Presumably 
after this time proteases have been secreted into the medium by the cells 
and begin degrading the peptide. The peptide was also lost when it was 
incubated with conditioned medium in the absence of the cells (Fig. 4.1C), 
confirming that peptide loss is due to some components present in the 
medium and not to uptake by cells. Supporting the idea that proteases 
secreted by cells in the medium are responsible for peptide loss, the 
addition of proteases inhibitors to the cell culture medium reduced peptide 
loss (Fig 4.1D). Furthermore, when the protease inhibitors were 
administered individually, peptide loss was reverted by aprotinin and 
leupeptin but not pepstatin (Fig. 4.1E).  
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Fig. 4.1. Uncoupled TNYL-RAW peptide is rapidly lost in cell culture medium, unless 
protease inhibitors are added. (A) Biotinylated TNYL-RAW peptide was added at a 
concentration of 1 µM to PC3 prostate cancer cells cultured overnight. Functional (EphB4- 
and streptavidin-binding) peptide remaining in the cell culture medium at the indicated 
times was captured in ELISA plates coated with neutravidin. Bound peptide was detected 
with EphB4 AP. The peptide is rapidly lost. (B) The same experiment as in (A) was carried 
out, except that the cell culture medium was replaced with fresh medium just before 
adding the peptide. The peptide remains intact for several hours before being degraded. 
(C) Conditioned medium was collected from cells and analyzed as in (A). The peptide was 
also lost in the absence of the cells. (D) The peptide was incubated with cell conditioned 
medium with and without a mixture of protease inhibitors including aprotinin, PMSF, 
leupeptin and pepstatin. The protease inhibitors reduce peptide loss. (E) PC3 cells 
conditioned medium containing proteases inhibitors all together or individually added was 
collected 40 min after the addition of TNYL-RAW and the peptide present was measured 
as described in (A). (F) The same experiment described in (E) was performed using 
medium from G6 glioma cells collected 180 min after the addition of TNYL-RAW. 
Averages from 3 measurements ± SD are shown in all the panels 
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Similar results were also obtained with C6 glioma cells (Fig. 4.1F) and 
BPH1 prostate epithelial cells (data not shown). Aprotinin is a well known 
inhibitor of serine protease, such as trypsin and chymotrypsin, which 
preferentially cleave peptidic bonds at the C terminus of arginine and lysine 
or aromatic residues, respectively. Leupeptin is an inhibitor of various 
proteases, including trypsin and cathepsin B, the latter preferentially 
cleaving bonds two-residues away from aromatic or positively charged 
residues. Being inhibited by both aprotinin and leupeptin, which reduced the 
inactivation of the peptide, trypsin-like proteases are possible candidates for 
the degradation of TNYL-RAW. The sequence of TNYL-RAW peptide is 
TNYLFSPNGPIARAW. If trypsin-like proteases are involved in TNYL-RAW 
degradation, the molecular bond at the C terminus of Arg 13 may be 
particularly susceptible to proteolysis, and could be therefore modified in 
order to improve the stability of the peptide. Examples of such modifications 
would be selective substitution of an amino acid with the corresponding D-
amino acid or chemical modifications such as methylation of a side chain.  
 
TNYL-RAW-PEG stability in cell culture medium 
Another known method to reduce peptide degradation and delay clearance 
through the reticuloendothelial system and the kidneys when administered 
in vivo is the coupling with PEG chains. TNYL-RAW was coupled with a 10 
kDa PEG molecule containing a succinimidyl α-methylbutanoate reactive 
group, which allows the coupling to the amino terminus of peptides and 
proteins. This approach was chosen because the crystal structure of TNYL-
RAW in complex with EphB4 showed that the amino-terminal T and N 
amino acids are not involved in binding to EphB4 (Chrencik et al., 2006). 
After the coupling reaction, the uncoupled peptide was removed by dialysis 
and the amount of PEGylated peptide was measured by optical density at 
280 nm. When an excess of PEG molecules was used, essentially all the 
peptide was coupled and the ratio between the PEGylated and the 
uncoupled peptide initially present in the reaction was about 1 (Fig. 4.2A).  
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Fig. 4.2. PEGylated TNYL-RAW peptide binds with high affinity to EphB4 and shows 
higher stability in cell culture medium compared to the uncoupled peptide. (A) 
TNYL-RAW peptide was covalently coupled to monofunctional 10 kDa PEG using 1:5 and 
3:1 ratios of peptide to PEG. After dialysis to remove unbound peptide, almost all the 
peptide was coupled to PEG (ratio between PEGylated TNYL-RAW and TNYL-RAW 
initially added to the reaction ~1) when an excess peptide was present during the coupling 
reaction (1:5 peptide to PEG ratio). In contrast, when an excess peptide was used (3:1 
peptide to PEG ratio) approximately one third of the peptide initially added was coupled. 
(B) PEGylated TNYL-RAW peptide was captured in ELISA wells coated with anti-PEG 
antibodies and detected with EphB4 AP. The signal with PEGylated peptide was higher 
than the background signal with peptide alone (dashed line). Averages from 2 
measurements ±SE are shown. (C) The PEGylated TNYL-RAW peptide was incubated at 
the indicated concentrations together with a constant concentration of EphB4 AP in ELISA 
wells pre-coated with protein A and ephrin-B2 Fc. The ratio of EphB4 AP bound in the 
presence and in the absence of peptide is shown. (D,E) Uncoupled (D) and PEGylated (E) 
TNYL-RAW peptide were incubated at the indicated concentrations in ELISA wells pre-
coated with protein A and EphB4 Fc. Bound peptide was detected with streptavidin-HRP. 
Averages from 3 measurements ±SE are shown in (B), (C), (D) and (E). (F) Uncoupled or 
PEGylated TNYL-RAW peptide was added to PC3 prostate cancer cells in culture. 
Functional (EphB4- and streptavidin-binding) peptide remaining in the cell culture medium 
at the indicated times was captured on neutravidin coated-plates and detected using 
EphB4 AP. (G) Conditioned medium was collected from cells and analyzed as in (F). 
Averages from 3 measurements ±SD are shown in (F) and (G). 
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On the contrary, when a 1:3 ratio of PEG molecules to peptide molecules 
was used, only one third of the peptide was PEGylated, as expected (Fig. 
4.2A). Coupling was verified by capturing the PEGylated peptide on ELISA 
protein L plates coated with anti-PEG antibody (AGP3) followed by 
detection with streptavidin-HRP (Fig. 4.2B). TNYL-RAW-PEG showed a 
significantly higher signal compared to the unmodified TNYL-RAW, 
demonstrating that the coupling reaction was successful. The PEGylated 
peptide retained the ability to inhibit EphB4-ephrin-B2 binding (Fig. 4.2C) 
and a high binding affinity for EphB4. The calculated dissociation constant 
(KD) for TNYL-RAW-PEG is comparable to the KD for the uncoupled peptide 
(Fig. 4.2D-E). Furthermore, the stability of the PEGylated peptide was 
tested in PC3 cell culture medium, showing an increased resistance to 
degradation compared to the non-PEGylated peptide (Fig. 4.2F), with an 
approximate 4 fold increase in the peptide half-life (t1/2).  When the 
PEGylated peptide was tested in cell culture supernatants in the absence of 
cells (Fig. 4.2G), an improvement in the half life was also observed, which 
was approximately 7 fold higher compared to TNYL-RAW.  
 
TNYL-RAW and TNYL-RAW-PEG retention in mouse blood 
The stability of the unmodified and PEGylated TNYL-RAW was also 
assessed in vivo. In this case a 40 KDa branched PEG was used, 
containing a succinimidyl-glutarate reactive group, which also allowed the 
coupling with the amino terminus of the peptide. A higher molecular weight 
was chosen for the in vivo experiments because it may help decrease 
filtration through the kidneys. In vitro, TNYL-RAW coupled with the 40 kDa 
PEG efficiently inhibited EphB4-ephrin-B2 interaction (Fig. 4.3A). However, 
peptide binding to EphB4 could not be detected by ELISA using 
streptavidin-HRP, presumably because the higher molecular weight PEG 
interferes with streptavidin binding to the biotin tag on the peptide. A slightly 
different assay was then used to detect the peptide, which involves the use 
of the AGP3 anti-PEG antibody followed by a secondary anti mouse IgM. 
The KD value obtained is comparable to that of the uncoupled peptide (Fig. 
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4.3B), showing that the binding to EphB4 is not altered by the presence of 
the larger PEG molecule. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Six µmol of the peptides were injected intravenously in mice and the 
blood was collected after 30 min, 2 hours and 6 hours. Serum was 
separated and the amount of peptide present in the serum was measured 
by ELISA after capturing it with EphB4 Fc. TNYL-RAW could not be 
detected in the serum at any of the time points (Fig. 4.3C), suggesting that 
Fig. 4.3. Coupling of TNYL-RAW to a 40 KDa branched PEG increases the peptide 
half-life in mouse serum. (A) TNYL-RAW peptide coupled to a 40 kDa PEG was 
incubated at the indicated concentrations together with a constant concentration of EphB4 
AP in ELISA wells pre-coated with protein A and ephrin-B2 Fc. Ratio of EphB4 AP bound 
in the presence and in the absence of peptide is shown. (B) TNYL-RAW-PEG diluted in 
100 µl of binding buffer to the indicated concentrations was incubated in ELISA Ni-coated 
wells pre-coated with EphB4 Fc. Bound peptide was detected with anti-PEG antibody and 
a secondary anti-mouse IgM. (C) Serum collected at the indicated times from mice 
injected with TNYL-RAW was incubated at a dilution of 1:10 in ELISA wells pre-coated 
with protein A and EphB4 Fc. Bound peptide was detected with streptavidin-HRP. TNYL-
RAW peptide at a concentration of 4 nM was used as a control. (D) 0.01 or 1 µl of serum 
collected at the indicated times from mice injected with TNYL-RAW-PEG was incubated in 
ELISA wells as described in (B) (right portion of the histogram). TNYL-RAW-PEG peptide 
at different concentrations in the presence of 0.01 or 1 µl of non-treated mouse serum was 
used as a control (left portion of the histogram). Averages from 3 measurements ±SE are 
shown in all the panels. 
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the unmodified peptide is rapidly lost. On the contrary, TNYL-RAW-PEG 
could be detected in mouse serum diluted up to 10,000 fold (Fig. 4.3D). By 
comparing the absorbance of peptide contained in the mouse serum with 
the absorbance of TNYL-RAW-PEG in the presence of equal amount of 
serum, the approximate concentration of peptide retained in mouse blood 
can be deduced. After 30 min, approximately all the peptide injected was 
still in the mouse serum (calculated concentration of 2 µM), after 2 hours 
the absorbance was reduced to about a half and after 6 hours the 
calculated concentration was about 0.025 µM. More time-points must be 
tested in order to better quantify the half-life of the PEGylated peptide, 
nevertheless the results obtained so far show that the presence of the PEG 
molecule highly enhances the in vivo stability of the peptide. 
 
Characterization of TNYL-RAW Fc 
A synthetic DNA sequence encoding the TNYL-RAW peptide was cloned in 
a vector encoding a signal peptide allowing secretion of the peptide in the 
culture medium and the Fc portion of human IgG1. The TNYL-RAW Fc 
fusion protein purified from HEK293 cell culture supernatants bound to 
EphB4 with substantial affinity (Fig. 4.4A). However, the KD of EphB4 AP 
binding to TNYL-RAW Fc and the IC50 value for inhibition of EphB4-ephrin-
B2 binding were approximately 17 and 14 times lower, respectively, 
compared to ephrin-B2 Fc (Fig. 4.4B-C). One possible explanation for the 
decreased affinity and inhibitory activity is that a portion of the TNYL-RAW 
Fc protein may become inactivated in the HEK293 cell culture medium 
before purification. Regardless, since the Fc fusion protein was purified 
from medium in which the producing HEK293 cells were grown for 4 days, 
the half-life of TNYL-RAW Fc appears to be much longer compared to the 
synthetic peptide, which is lost within several hours in cell culture medium. 
Therefore, fusion to Fc appears to effectively stabilize the peptide.  
In order to verify that the fusion with the Fc portion of human IgG1 
improves the stability of TNYL-RAW peptide also in vivo, TNYL-RAW Fc 
retention in mouse blood will be examined. The binding properties and the 
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stability of TNYL-RAW-PEG and TNYL-RAW Fc will be compared and the 
best form of the peptide will be selected to be tested in tumor xenograft 
studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4. Characterization of TNYL-RAW peptide fused to human Fc. (A) TNYL-RAW 
Fc immobilized on protein A-coated ELISA plates binds EphB4 AP; human Fc was used 
as a control. (B) The indicated amounts of EphB4 AP were added to ELISA wells 
precoated with 0.03 µg/well of ephrin-B2 Fc or TNYL-RAW Fc. Measured AP activity was 
normalized to the maximum binding for each curve calculated using non linear regression. 
KD values were based on EphB4 AP concentration as calculated from AP activity. (C) 
TNYL-RAW or TNYL-RAW Fc were incubated at the indicated concentrations together 
with a constant amount of EphB4 AP in ELISA wells pre-coated with protein A and ephrin-
B2 Fc. Ratio of EphB4 AP bound in the presence and in the absence of peptide is shown. 
Averages from 3 measurements ±SE are shown in all the panels. 
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Chapter 5 
 
Conclusions 
 
The Eph receptors and their ligands, the ephrins, are involved in many 
physiological and pathological processes. Inhibitors of their interaction could 
therefore be useful to help elucidate the mechanism of receptor-ligand 
interaction, for characterizing the functions of Eph receptors and ephrins in 
disease, and as leads for drug development. Agents targeting the 
extracellular domain of the Eph receptors are advantageous with respect to 
tyrosine kinase inhibitors in that they can act without penetrating inside the 
cells and they can be highly selective. Although ephrin binding to Eph 
receptors is very promiscuous, the characterization of peptides identified by 
phage display demonstrated that it is possible to selectively target only one 
of the Eph receptors. This is a highly desirable feature in order to inhibit the 
pathological function of a specific receptor, without affecting the numerous 
physiological functions of the other receptors.  
In this study we applied 2 different screening approaches, high 
throughput screening and combinatorial library screening, to the 
identification of chemical compounds that target EphA4 and EphA2. Two 
2,5-dimethylpyrrolyl benzoic acid derivatives were identified in the high 
throughput screen for EphA4 antagonists. These compounds inhibit ephrin 
binding to EphA4 and EphA2 but no other Eph receptors. These results are 
completely novel because no small molecule inhibitors of Eph receptor-
ephrin interaction have been identified so far. Importantly, they demonstrate 
that the Eph receptors can be successfully targeted by small molecules. 
The activity and selectivity of the two compounds are particularly 
impressive, given the large size of the ephrin-binding pocket in the Eph 
receptors and the small size of the compounds. Intriguingly, the 2 2,5-
dimethylpyrrolyl benzoic acid derivatives also show selectivity in their 
inhibition of the binding of different ephrins to EphA4 and EphA2. This 
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suggests that  ephrin-A4, ephrin-B1 and ephrin-B2 bind differently to EphA4 
compared to other ephrins of the same class. Virtual docking or NMR 
analysis of the compounds in complex with EphA4 and EphA2 will help 
clarify the molecular basis for these differences.  
The 2 2,5-dimethylpyrrolyl benzoic acid derivatives also inhibit EphA4 
and EphA2 phosphorylation in cells as well as the characteristic biological 
activities of the 2 receptors, such as retraction of the cell periphery and 
growth cone collapse. On the other hand, the compounds do not affect cell 
and growth cone morphology in the absence of ephrin treatment or cell 
viability. Thus, these compounds could be useful as inhibitors of EphA4 or 
EphA2-dependent pathological processes, such as cancer progression, 
pathological blood clotting and inhibition of spinal cord regeneration after 
injury provided that a higher potency is achieved. The design other 2,5-
dimethylpyrrolyl benzene derivatives with structural modifications based on 
the structure-activity relationships observed for inhibition of EphA4-KYL 
binding is anticipated to result in the identification of compounds retaining 
the original functional activity and selectivity but having increased potency.  
By combinatorial library screening, we also identified platinum(II) 
tetraamines as potential inhibitors of EphA2 activity. EphA2 inhibitors can 
have application in the treatment of tumor angiogenesis and other forms of 
pathological angiogenesis. The platinum(II) tetraamine library seems to 
inhibit ephrin-A1 and ephrin-A5 binding to EphA2 in a specific manner 
because no effect was observed when the platinum(II) tetraamine library 
was tested for inhibition of 2 other Eph-ephrin interactions. All the other 
receptors will be tested once the compounds responsible for the activity 
observed in the mixtures will be identified. Nevertheless, this preliminary 
result suggests that the compounds are likely to be selective for one or few 
Eph receptors. In particular, the platinum(II) tetraamines did not inhibit 
EphA4, a receptor that is highly related to EphA2 and that is not 
discriminated from EphA2 by the 2,5-dimethylpyrrolyl benzoic acid 
derivatives. In addition, the same tetraamine libraries without the 
coordinated platinum have poor activity, indicating that the structural 
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conformation conferred by the metal is necessary for the activity of these 
compounds. A drawback of platinum-containing compounds, however, is 
that the release of platinum could create some toxicity problems in cell 
culture and in vivo. In any case, these compounds could represent useful 
leads for the development of other, platinum-free compounds with similar 
structures. 
TNYL-RAW, a peptide antagonist that targets the EphB4 receptor 
also has potential applications for the treatment of different forms of cancer 
and pathological forms of angiogenesis. The TNYL-RAW peptide shows 
promising features, since it is highly selective, has nanomolar affinity for 
EphB4 and has been shown to inhibit capillary-like structures in vitro. 
However, peptides are known to be highly unstable in physiological fluids. 
This was confirmed by our results, which show that the unmodified TNYL-
RAW peptide is rapidly lost both in cell culture medium and in the mouse 
blood. This effect is due at least in part to proteolitic degradation, because 
the peptide persists longer in cell culture medium when protease inhibitors 
are present. Further studies using different protease inhibitors will help 
identify the peptide bonds that are particularly susceptible of proteolitic 
degradation, enabling synthesis of peptides carrying modifications at those 
bonds. Coupling to PEG or Fc were also found to increase the stability of 
the peptide in cell culture medium and, in the case of PEGylation, also in 
mouse blood. The in vivo stability of TNYL-RAW Fc remains to be 
examined, although Fc fusion proteins including antibodies are typically 
extremely stable in vivo. These results are encouraging for the possible use 
of TNYL-RAW in vivo to inhibit cancer progression and angiogenesis. 
Pharmacological tools to manipulate Eph receptor function will open 
new avenues of research and therapy. By identifying new chemical 
compounds with expected better pharmacological properties compared to 
the previously identified agents and by improving the properties of a known 
peptide inhibitor we obtained some promising results for Eph receptor 
targeting. 
 Chapter 5 
 92 
Furthermore, our studies are the first to show the feasibility of 
approaches to identify agents targeting the extracellular domain of this large 
and important class of receptors, approaches that can be used with other 
receptors and have therefore wide application.  
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